



24 **Abstract**

25 Generating recombinant monoclonal antibodies (R-mAbs) from mAb-producing hybridomas offers  
26 numerous advantages that increase the effectiveness, reproducibility, and transparent reporting  
27 of research. We report here the generation of a novel resource in the form of a library of  
28 recombinant R-mAbs validated for neuroscience research. We cloned immunoglobulin G (IgG)  
29 variable domains from cryopreserved hybridoma cells and input them into an integrated pipeline  
30 for expression and validation of functional R-mAbs. To improve efficiency over standard protocols,  
31 we eliminated aberrant Sp2/O-Ag14 hybridoma-derived variable light transcripts using restriction  
32 enzyme treatment. Further, we engineered a plasmid backbone that allows for switching of the  
33 IgG subclasses without altering target binding specificity to generate R-mAbs useful in  
34 simultaneous multiplex labeling experiments not previously possible. The method was also  
35 employed to rescue IgG variable sequences and generate functional R-mAbs from a non-viable  
36 cryopreserved hybridoma. All R-mAb sequences and plasmids will be archived and disseminated  
37 from open source suppliers.

## 38 **Introduction**

39 Antibodies (Abs) are the workhorses of biomedical research. Enhancing the research  
40 community's access to extensively validated Abs remains an important goal of antibody  
41 developers in both academia and industry (1). This has been the topic of a number of recent  
42 conferences and commentaries, led to changes in journal practices as related to transparent  
43 reporting of antibody-based research including the use of RRIDs, and resulted in large-scale NIH  
44 and EU Ab development initiatives (*e.g.*, the NIH Common Fund Protein Capture Reagent  
45 Program, the EU Affinomics Program). It is widely recognized that production of Abs in a  
46 renewable form, such as monoclonal antibodies (mAbs), represents a substantial advance over  
47 polyclonal Abs from antisera that are available in finite quantity, and that comprise a  
48 heterogeneous and less definable population of Abs (2-4). Having mAbs available in recombinant  
49 form as recombinant mAbs (R-mAbs) offers numerous additional advantages (5). Recombinant  
50 expression systems allow for the reliable production of an R-mAb not prone to loss by genetic  
51 instability of tetra- or hexa-ploid hybridoma cells or other factors (6, 7). Moreover, unlike  
52 hybridoma cell lines that can express multiple functional heavy and light immunoglobulin chains  
53 (8-10), recombinant expression ensures production of a single, molecularly defined R-mAb.  
54 Recombinant expression can also yield production levels 100s or 1000s of times higher than is  
55 possible with endogenous expressions of mAbs from hybridoma cells [*e.g.*, (11-13), etc.].  
56 Furthermore, the cloning of R-mAbs provides for permanent, dependable and inexpensive  
57 archiving of the R-mAb as plasmid DNA and nucleic acid sequences versus an archiving system  
58 relying on expensive cryopreservation of hybridoma cell lines in liquid nitrogen, and their  
59 subsequent recovery as viable cell cultures. The conversion of existing mAbs to R-mAbs also  
60 allows for more effective dissemination of R-mAbs as plasmids, bacterial stocks or as DNA  
61 sequences. However, in spite of these advantages, it remains that most mAbs used for research  
62 are produced by hybridomas in culture.

63 Modern techniques employing Abs as immunolabels [e.g., immunoblotting (IB),  
64 immunocytochemistry (ICC) and immunohistochemistry (IHC)] utilize simultaneous multiplexing  
65 of numerous Abs to simultaneously detect multiple targets within a single cell or tissue sample.  
66 This allows for direct comparison of the relative amounts and respective characteristics of multiple  
67 target molecules within the same sample, while reducing the number of samples needed to  
68 accomplish a comprehensive analysis. Typically, the individual primary Abs bound to the sample  
69 are detected with secondary antibodies conjugated to distinct reporters, most commonly organic  
70 fluorescent dyes, although enzymes, gold particles, etc. are also routinely employed as detection  
71 modalities. Multiplex labeling is often accomplished using Abs raised in distinct species, with their  
72 subsequent individual detection accomplished using species-specific secondary antibodies.  
73 However, mouse mAbs offer an important advantage for multiplex labeling procedures. Each  
74 mouse mAb is a single immunoglobulin (Ig) isotype, generally of the IgG class and if so specifically  
75 of a single IgG subclass, most commonly IgG1, IgG2a or IgG2b. Mouse mAbs of distinct IgG  
76 subclasses can be robustly, reliably and specifically detected with commercial subclass-specific  
77 secondary antibodies, and, as such, can be multiplexed in a manner analogous to Abs from  
78 different species [e.g., (14-18)]. One limitation to greater adoption of this approach is that mouse  
79 mAb collections generally have an extremely high representation ( $\approx 70\%$ ) of IgG1 mAbs (18),  
80 which limits the flexibility of multiplex labeling. The conversion of mAbs into R-mAbs allows for  
81 their subsequent engineering into forms with properties distinct from their parent mAb, as is  
82 routinely done to impact diverse aspects, including target binding affinity, of therapeutic R-mAbs  
83 (19). Such engineering could also include switching the heavy chain constant region to impact  
84 subclass-specific secondary Ab binding specificity, an approach similar to that used to  
85 successfully modify subclass-specific *in vivo* effector functions (20).

86 There are numerous routes to obtaining validated R-mAbs, including their *de novo*  
87 generation from high complexity immune repertoire libraries produced from naïve or immunized  
88 animals, combined with selection of target-specific R-mAbs by *in vitro* display (21). Alternatively,

89 R-mAbs can be generated from existing hybridoma cell lines, which express well-characterized  
90 mAbs [e.g., (22)]. Here we undertook conversion of a widely used collection of hybridoma-  
91 generated mAbs extensively validated for neuroscience research applications (14, 23, 24) into  
92 recombinant form. We developed a coherent pipeline of protocols for effective cloning of intact R-  
93 mAbs from cryopreserved hybridoma cells and their subsequent validation compared to their  
94 parent mAbs. Further, we developed a process to engineer these R-mAbs to IgG subclass-  
95 switched forms that provide additional utility for multiplex labeling employing mouse IgG subclass-  
96 specific secondary Abs. This approach is feasible and relatively inexpensive for any laboratory  
97 that uses standard molecular biology and mammalian cell culture techniques. This approach also  
98 represents a reliable method to convert valuable cryopreserved hybridoma collections to the  
99 immortalized form of a DNA sequence archive, including hybridomas that are no longer viable in  
100 cell culture.

101

## 102 **Results**

### 103 **Effective Cloning of Immunoglobulin V<sub>H</sub> and V<sub>L</sub> Regions from Cryopreserved Hybridomas** 104 **and Generation of R-mAbs**

105 We previously generated a large library of mouse mAbs that have been extensively validated for  
106 efficacy and specificity for immunolabeling endogenous target proteins in mammalian brain  
107 samples in immunoblotting (IB) and immunohistochemistry (IHC) applications (14, 23, 24). Here,  
108 we undertook the systematic conversion of a sizable subset of this existing mAb collection to R-  
109 mAbs. We developed an innovative pipeline for R-mAb cloning, expression and validation. For  
110 the cloning steps, we built upon a previously described method (22, 25) to clone IgG V<sub>H</sub> and V<sub>L</sub>  
111 region sequences, but with the modification that we cloned directly from cryopreserved  
112 hybridomas, without the need for their labor-intensive recovery into cell culture. Our overall  
113 cloning strategy (Figure 1A) employs PCR-mediated amplification to generate IgG V<sub>H</sub> and V<sub>L</sub>  
114 region sequences from hybridoma-derived cDNA, followed by PCR-based fusion of these V<sub>H</sub> and

115 V<sub>L</sub> regions with a joining fragment that contains a subset of the elements needed for high level  
116 expression of R-mAbs from transfected mammalian cell lines. The product of this fusion PCR  
117 reaction is then inserted into a plasmid containing the remainder of the elements for propagation  
118 in bacteria and expression of intact heavy and light chains in, and secretion of R-mAbs from,  
119 transfected mammalian cells (Figure 1B).

120 We extracted RNA from cryopreserved hybridoma cell vials, followed by first strand cDNA  
121 synthesis and RT-PCR of the IgG V<sub>H</sub> and V<sub>L</sub> region sequences (Figure 1A). To enhance  
122 throughput, we performed the first three steps of this process in a 96 well plate format. We  
123 obtained hybridoma cells directly from cryovials and added an aliquot of 1-3 x 10<sup>6</sup> cells to  
124 individual wells of a commercially available 96 well RNA extraction plate. After performing the  
125 RNA isolation procedure in the 96 well plate, we replica plated 1/16 of the extract volume to a  
126 second 96 well plate for first strand cDNA synthesis. Following the cDNA synthesis reaction, we  
127 replica plated ≈5% of the volume of the cDNA synthesis product to a third 96 well plate to serve  
128 as the template for PCR amplification of the IgG V<sub>H</sub> and V<sub>L</sub> domain sequences. As such, the  
129 templates for the V<sub>H</sub> and V<sub>L</sub> domain PCR amplification represented the cDNA yield from ≈3,000-  
130 7,500 hybridoma cells. We amplified the IgG V<sub>L</sub> kappa (κ) and V<sub>H</sub> domain sequences from the  
131 hybridoma cDNA templates using a degenerate mouse Ig variable region primer set developed  
132 by Gavin Wright and colleagues (22) expanding on a previously used set (33) that at the time of  
133 their design recognized 97% and 98% of known functional heavy and kappa (κ) light chain  
134 sequences, respectively. Lambda light chains were not targeted for amplification because they  
135 constitute only a small percentage of light chains used in mouse immunoglobulins (34, 35). This  
136 PCR amplification reliably gave products of the expected 360 base pairs (bp) for both the V<sub>L</sub> and  
137 V<sub>H</sub> domain sequences, examples of which are shown in Figure 2A for representative mAbs  
138 N59/36 (“N59”, anti-NR2B/GRIN2B glutamate receptor) and K39/25 (“K39”, anti-Kv2.1/KCNB1  
139 potassium channel).

140 To permit cloning of both the  $V_H$  and  $V_L$  regions into a single expression vector, fusion  
141 PCR (F-PCR) was performed using as templates the  $V_H$  and  $V_L$  PCR products, as well as a joining  
142 fragment amplified from the P1316 expression plasmid (22, 25) to produce a 2.4 kbp amplicon  
143 (Figure 2B). The joining fragment (Figure 1B) contains kappa light chain constant region  
144 sequences and an associated polyadenylation signal, followed by a CMV promoter to drive  $V_H$   
145 expression, and a  $V_H$  leader sequence (22, 25). The F-PCR reaction products were then treated  
146 with NotI and Ascl restriction enzymes and purified in preparation for cloning into a NotI/Ascl  
147 restriction enzyme-digested fragment of the P1316 expression plasmid (Figure 1B). Upstream of  
148 the NotI cloning site, the digested P1316 fragment contains a CMV promoter to drive light chain  
149 expression and a  $V_L$  leader sequence, and downstream of the Ascl cloning site a mouse IgG1  $C_H$   
150 sequence, and a polyadenylation signal (Figure 1B). Standard methods were used for DNA  
151 ligation and subsequent transformation of *E. coli*. Clones expressing the full-length IgG  
152 expression cassette were identified by colony PCR (Figure 2C). Following NotI/Ascl restriction  
153 digestion to verify the correct insert size (Figure 2D), these plasmid clones were subjected to  
154 further analysis (Figure 1A), including expression in mammalian cells, and R-mAb validation and  
155 sequencing as detailed in the subsequent sections.

156 While a number of *bona fide* R-mAbs were isolated using this approach, we found a high  
157 degree of variability in the number of colony PCR- and restriction enzyme digest- verified positive  
158 plasmids that yielded functional expression. A major obstacle in cloning functionally rearranged  
159 IgG sequences from many mouse hybridomas is the presence of an aberrant kappa IgG light  
160 chain transcript expressed by the Sp2/0-Ag14 (Sp2/0) hybridoma (36) that frequently serves as a  
161 “myeloma” partner for fusion with mouse splenocytes to generate mAb-producing hybridomas  
162 (37), and that was used as the fusion partner in all of our mAb generation efforts (14, 24). The  
163 source of this non-productive IgG light chain is the MOPC-21 myeloma cell line used to generate  
164 the Sp2/0 hybridoma (37). As we experienced, and as previously reported by others (36), aberrant  
165 chain mRNA expression varies greatly among distinct hybridoma cell lines but in certain cases

166 can exceed the levels of functional light chain transcripts. For certain of our projects, this resulted  
167 in >90% of the colony PCR positive clones failing to produce detectable levels of functional R-  
168 mAbs, thus necessitating a high volume of screening.

169 As such, we sought to eliminate this aberrant light chain during the cloning process. We  
170 treated the  $V_L$  PCR products with the restriction enzyme BciVI, as the restriction site for this  
171 enzyme is present in the  $V_L$  region of the aberrant Sp2/0-derived transcript, but is predicted to  
172 occur at a low frequency in functional mouse  $V_L$  kappa sequences (38). We used  $V_L$  PCR products  
173 derived from the Sp2/0 cell line and from pooled BALB/c mouse splenocytes as positive and  
174 negative controls, respectively, for sensitivity to BciVI digestion. Due to the exclusive presence of  
175 aberrant light chain in Sp2/0 cells,  $V_L$  PCR products from these cells were completely digested,  
176 as shown by the decreased size of the  $V_L$  PCR products from  $\approx 360$  bp typical of  $V_L$  PCR products  
177 (see Figure 2A for examples) to the  $\approx 180$  bp fragment that results from BciVI digestion (Figure  
178 2E). In contrast, the sample prepared from the pooled mouse splenocytes was not detectably  
179 affected by BciVI digestion (Figure 2E). Treatment of  $V_L$  PCR products from various Sp2/0-derived  
180 hybridomas with BciVI resulted in varying degrees of digestion, yielding different proportions of  
181 the bands representing the intact  $V_L$  PCR product of  $\approx 360$  bp and the cleaved aberrant SP2/0-  
182 derived  $V_L$  fragment of  $\approx 180$  bp (Figure 2E). After BciVI digestion was incorporated into the  
183 protocol, DNA sequencing of 149 colony PCR-positive clones from 26 different hybridomas  
184 revealed that only 12 (8%) still contained the aberrant  $V_k$  light chain (Table 1). In certain cases,  
185 digestion of hybridoma  $V_L$  PCR products resulted in fragments of unexpected sizes (see the  
186 K58/35 lane in Figure 2E), indicating, as predicted by an earlier bioinformatics analysis (38), that  
187 in rare cases (in our hands, 3/248 clones pursued to this step) the BciVI restriction site was also  
188 present in these functionally rearranged splenocyte-derived  $V_L$  genes. As such, we attempted to  
189 clone these  $V_L$  PCR products without BciVI treatment. As one example, the splenocyte-derived  $V_k$   
190 light chain PCR products from the K58/35 hybridoma were sensitive to BciVI digestion, which  
191 necessitated their cloning in the absence of the BciVI digestion step. This project yielded



192 somewhat lower frequency of clones that produced functional R-mAbs able to detect target  
193 antigen ( $\approx 37\%$ ) than, on average, those containing splenocyte-derived  $V_L$  PCR products refractory  
194 to BciVI digestion ( $\approx 48\%$ ; Table 2). For the bulk of mAbs encoded by splenocyte-derived  $V_L$  PCR  
195 products resistant to BciVI digestion, ligations were performed following BciVI digestion, and 10-  
196 14 candidate clones that were colony PCR-positive were selected. Plasmid DNA was digested  
197 with AscI/NotI restriction enzymes to confirm the correct insert (Figure 2D). On average,  $\approx 93\%$  of  
198 all clones subjected to restriction analysis passed this screening step.

199 We next transfected the colony PCR and restriction digest-validated plasmids into COS-1  
200 cells cultured in 12 well or 96 well tissue culture plates. After a 3 to 6 day incubation, we tested  
201 the conditioned culture media for production of target-specific R-mAbs. While the parent mAbs  
202 had previously been validated for efficacy and specificity in a variety of applications (IF-ICC, IB  
203 and IHC on brain samples), we selected the IF-ICC assay in transiently transfected heterologous  
204 cells for R-mAb validation. This method was chosen because it is high-throughput, employing 96  
205 well microtiter plates, it requires only a small amount of R-mAb sample, and the robust difference  
206 between target-expressing and non-expressing cells in the same sample allows for sensitivity and  
207 clarity of results. Importantly, each of the parent mAbs had been previously validated in this  
208 procedure. We took advantage of the fact that in most cases we switched the IgG subclass during  
209 conversion of the hybridoma-derived mAb into the corresponding R-mAb, allowing for their  
210 separate detection by subclass-specific secondary Abs (18). This assay involved expressing the  
211 full-length target protein in transiently transfected COS-1 cells cultured in individual wells of a  
212 black polystyrene 96 well clear bottom plate that allows for microscopic visual analysis and  
213 imaging using indirect immunofluorescence. For each of 1 to 15 R-mAb candidate clones to be  
214 assayed from a given project, a set of replicate wells were prepared expressing the given target  
215 protein. After fixation and permeabilization, the individual wells were then immunolabeled with  
216 either the hybridoma-generated mAb alone, the R-mAb alone, or the mAb and R-mAb together.  
217 Each well was subsequently incubated with a cocktail of the two distinct subclass-specific

218 secondary Abs, one specific for the respective mAb and one specific for the subclass-switched  
219 R-mAb mouse IgG subclasses, and both conjugated to spectrally distinct Alexa Fluors. The “mAb  
220 only” well was used to demonstrate that the target protein was expressed in a subset of the  
221 transiently transfected cells, and that the only detectable secondary Ab labeling was for the IgG  
222 subclass of the parent hybridoma-generated mAb. Similarly, the R-mAb only wells were used to  
223 show that the R-mAb labeled a comparable number of cells, and that the only detectable  
224 secondary Ab labeling was for the IgG subclass of the subclass-switched R-mAb. The wells  
225 containing both the parent mAb and candidate R-mAb were used to show that the mAb and R-  
226 mAb gave indistinguishable labeling patterns at both the cellular and subcellular level and could  
227 be detected separately using subclass-specific secondary Abs. Numerous examples of this assay  
228 are shown in the following sections focusing on specific R-mAb projects. We note that only in rare  
229 cases was the labeling for one or both secondaries noticeably depressed in the well containing  
230 both mAb and R-mAb relative to the wells with these primary antibodies alone, as would occur  
231 due to competitive binding to the same epitope. However, this was generally not apparent,  
232 suggesting that in this assay system, in which the target protein was overexpressed, we were  
233 typically operating under conditions of antigen excess.

234 In comparing the overall results from 180 recent projects that had BciVI-resistant  
235 splenocyte-derived  $V_L$  PCR products, and that were taken through this entire pipeline one time  
236 (Table 2), we found that a range of 1-15 colony PCR- and restriction digest-positive candidate R-  
237 mAbs per project were evaluated in the COS-ICC assay (919 total, mean/project =  $5.11 \pm 0.23$   
238 S.E.M.). For these 180 projects, cloning was performed after BciVI digestion, and all restriction  
239 digest-validated candidates were tested for functional mAb production. Of these 180 projects,  
240 72% (129 projects) yielded at least one positive R-mAb on their first pass through the pipeline. A  
241 retrospective analysis of these 129 successful projects revealed a range of 1 to 13 restriction  
242 digest-validated candidates were evaluated (mean/project =  $5.74 \pm 0.26$  S.E.M.), with an overall  
243 success rate of 48.4% for all 741 restriction digest-validated candidate R-mAbs tested. A parallel

244 analysis of the 51 projects that did not yield a positive R-mAb on their first pass through the  
245 pipeline revealed a similar range of 1 to 15 restriction digest-validated candidates per project  
246 evaluated. However, an overall lower number of colony PCR- and restriction digest-positive  
247 candidates were evaluated in the COS-ICC assay (178 total, mean/project =  $3.5 \pm 0.37$  S.E.M.)  
248 in these projects than for the successful projects. A statistically significant difference (two-tailed  
249 P value =  $2.48 \times 10^{-6}$ ) existed between the number of candidates evaluated in successful versus  
250 unsuccessful projects. The per-project COS-ICC rate success was impacted by number of clones  
251 tested. For 1-3 clones tested (66 projects), the project success rate was 50%, for 4-6 (62 projects)  
252 it was  $\approx 77\%$ , and for  $\geq 7$  (52 projects) it was  $\approx 92\%$ . However, the per clone success rate was  
253 similar between the three bins ( $\approx 45\%$  vs.  $\approx 39\%$  vs.  $\approx 45\%$ ).

254       Following validation in the COS-ICC assay, a subset of positive clones for each project  
255 was subjected to DNA sequencing. We employed a set of sequencing primers that allowed for  
256 determination of sense and antisense strands of the  $V_H$  and  $V_L$  domain-encoding cDNA inserts  
257 that were unique to each R-mAb. The sequences were searched against the NCBI database, and  
258 against a custom database that contained the  $V_H$  and  $V_L$  domain sequences of the parent P1316  
259 plasmid, the  $V_L$  domain of the aberrant Sp2/0 cell line, and the  $V_H$  and  $V_L$  domain sequences of  
260 all of the R-mAbs we had cloned to date. The set of COS-ICC validated R-mAb plasmids derived  
261 from a single hybridoma that had matching sequences unique from any sequences in the custom  
262 database were subsequently archived as frozen plasmid DNA and bacterial glycerol stocks, and  
263 their sequence used as the archival sequence of that particular R-mAb.

264

### 265 **Effective Cloning and IgG Subclass Switching of a Widely Used Monoclonal Antibody**

266 We initiated our R-mAb cloning efforts with the K28/43 mAb, a mouse mAb specific for the neural  
267 scaffolding protein PSD-95. This mAb is widely used as a marker of excitatory synapses (*e.g.*, as  
268 of 7/1/18  $\approx 500$  publications have cited the use of the K28/43 mAb as obtained from the UC  
269 Davis/NIH NeuroMab Facility alone). While the K28/43 mAb is already of a less common IgG

270 subclass (IgG2a), generating a subclass switched version with an alternate IgG subclass would  
271 provide greater flexibility in its use in multiplex labeling experiments, and also provide proof of  
272 concept that we could use our process to effectively generate subclass switched R-mAbs with  
273 efficacy and specificity comparable to the parent mAb. We generated V<sub>L</sub> and V<sub>H</sub> domain cDNA  
274 fragments from the cryopreserved K28/43 hybridoma and cloned them into the original P1316  
275 plasmid that contains a mouse IgG1 C<sub>H</sub> domain (22). COS-1 cells were transiently transfected  
276 with the resultant plasmids. We evaluated the conditioned medium from the transfected cells for  
277 the presence of the subclass-switched K28/43R IgG1 R-mAb by ICC against fixed and  
278 permeabilized transiently transfected COS-1 cells expressing full-length PSD-95 (Figure 3A). We  
279 note that we have designated the recombinant R-mAb versions of each of our mAbs by a capital  
280 “R” after the clone designation, in this case the R-mAb cloned from the K28/43 hybridoma is  
281 designated K28/43R. We screened the COS-1 cell-generated R-mAbs for functional R-mAb  
282 immunoreactivity in the 96-well IF-ICC assay detailed in the previous section. After primary  
283 antibody labeling, all wells received both IgG1- and IgG2a-subclass-specific, fluorescently labeled  
284 secondary antibodies. As shown in Figure 3A, as expected, the sample receiving only the native  
285 K28/43 hybridoma-generated mAb exhibited a signal corresponding to the IgG2a subclass-  
286 specific secondary Ab (red) with no detectable signal for the IgG1 subclass-specific secondary  
287 Ab (green). Conversely, labeling with the K28/43R R-mAb alone produced only an IgG1 subclass-  
288 specific green signal demonstrating a successful IgG subclass switch for the R-mAb (Figure 3A).  
289 Simultaneous multiplex labeling with the hybridoma-generated mAb and a positive R-mAb  
290 resulted in an identical pattern of immunolabeling at the cellular level in the specific cells  
291 recognized, and at the subcellular level as to the pattern of immunolabeling within the labeled  
292 cells, as shown by the uniform hue of the signal in the merged panel, indicating that both the mAb  
293 and R-mAb were recognizing the same target (Figure 3A). We next performed multiplex  
294 immunofluorescent IHC on adult mouse brain sections with the K28/43 mAb and the K28/43R R-  
295 mAb. As shown in Figure 3B, as detected with secondary Abs specific for their respective mouse

296 IgG subclasses, the signal from these two primary antibodies was indistinguishable in its laminar  
297 and subcellular pattern in cerebellar cortex, consistent with previous studies of PSD-95 [e.g.,  
298 (39)]. Both signals were especially intense in the terminal pinceau of basket cells located adjacent  
299 to the Purkinje cell layer, and both signals were also present in the molecular layer, and for the  
300 most part lacking in the granule cell layer (Figure 3B). This demonstrates that consistent with the  
301 validation in heterologous COS-1 cells expressing exogenous PSD-95, the K28/43 R-mAb can  
302 be used reliably for multiplex immunolabeling of endogenous PSD-95 in brain sections.

303         The specificity of recombinant K28/43R was also assessed on immunoblots of samples  
304 from COS-1 cells exogenously expressing various representatives of the MAGUK superfamily of  
305 scaffolding proteins, of which PSD-95 is one member (Figure 3C-D). Immunoblots were probed  
306 with a rabbit polyclonal antibody raised against PSD-95 and that also cross-reacts with SAP97 as  
307 a positive control, and recombinant K28/43R in either the IgG1 or IgG2a mouse IgG subclass  
308 form (Figure 3C-D). Generation of the IgG2a expression plasmid is described below. Both the  
309 IgG1 and IgG2a subclass isoforms of the K28/43R R-mAb gave identical immunolabeling patterns  
310 against samples from rat brain and COS-1 cells overexpressing PSD-95. Moreover, the pattern  
311 of R-mAb immunolabeling was similar to that obtained with the rabbit polyclonal antibody, and  
312 absent against samples of COS-1 cells exogenously expressing other MAGUK superfamily  
313 members (Figure 3C-D). To confirm expression of these MAGUK proteins, immunoblots were  
314 probed with rabbit polyclonal anti-PSD-95 and with the hybridoma-generated K28/43 mAb (IgG2a)  
315 or a mAb that recognizes all mammalian MAGUK proteins mAb (K28/86; IgG1) (27) (Figure 3E).  
316 These initial results demonstrated that we could use this cloning and expression process to  
317 generate and validate subclass-switched R-mAbs that recapitulate the immunolabeling  
318 characteristics of the native mAbs.

319

320

321 **Generation of an R-mAb Expression Plasmid with an IgG2a C<sub>H</sub> Backbone Allows for**  
322 **Effective Subclass Switching of mAbs from Prevalent IgG1 Subclass**

323 Most (~70%) mouse IgG mAbs are of the IgG1 subclass (18). Generating R-mAbs employing the  
324 efficient V<sub>H</sub> and V<sub>L</sub> cloning approach developed by Gavin Wright and colleagues includes their  
325 subsequent insertion into an expression plasmid that yields R-mAbs of the mouse IgG1 subclass  
326 due to the presence of the mouse  $\gamma$ 1 C<sub>H</sub> domain in the plasmid backbone (22). To generate R-  
327 mAbs of less common mouse IgG subclasses, we set out to modify this plasmid by replacing this  
328  $\gamma$ 1 C<sub>H</sub> domain with a mouse  $\gamma$ 2a C<sub>H</sub> domain. We developed PCR primers to amplify the  $\gamma$ 2a C<sub>H</sub>  
329 domain sequence from cDNA generated from the hybridomas producing the K28/43 IgG2a mAb.  
330 We then replaced the  $\gamma$ 1 C<sub>H</sub> domain present in the K28/43R plasmid with this  $\gamma$ 2a C<sub>H</sub> domain using  
331 restriction digestion, gel isolation and ligation. This plasmid was sequenced verified and validated  
332 for expression of a K28/43R R-mAb of the IgG2a subclass (Figure 3C).

333 We subsequently used this plasmid as the target cloning vector for generation and  
334 expression of numerous R-mAb plasmids encoding functional IgG2a R-mAbs. Our strategy  
335 entailed cloning all native IgG1 and IgG2b mAbs into this plasmid to generate forms distinct from  
336 the parent native mAbs. Toward this end, we have successfully cloned and validated as functional  
337 R-mAbs a total of 178 mAbs (Table 3). This includes 148 mAbs of distinct subclasses converted  
338 to IgG2a R-mAbs (125 IgG1, 21 IgG2b, and 3 IgG3), and 29 IgG2a mAbs that were retained in  
339 their native IgG subclass (Table 3). We also converted the IgG2a mAb K28/43 to an IgG1 R-mAb.  
340 Each of these R-mAbs have been assigned unique RRID numbers in the Antibody Registry (Table  
341 3) and all will be deposited in plasmid form at Addgene, a subset of which are already available  
342 ([https://www.addgene.org/James\\_Trimmer/](https://www.addgene.org/James_Trimmer/)).

343

344

345

## 346 **Multiplex brain immunofluorescent labeling with subclass switched R-mAbs**

347 One benefit of subclass switching R-mAbs is the ability to perform multiplex immunolabeling  
348 previously not possible due to subclass conflicts. Examples of such enrichment in cellular protein  
349 localization are shown in Figure 4. Figure 4A shows labeling with the subclass switched IgG2a R-  
350 mAb derived from the widely used pan-voltage-gated sodium channel or “pan-Nav channel” IgG1  
351 mAb K58/35 (40). Like the corresponding mAb, K58/35 R-mAb gives robust labeling of Nav  
352 channels concentrated on the axon initial segment (AIS, arrows in Figure 4A main panel), and at  
353 nodes of Ranvier (arrows in Figure 4A insets). Importantly, subclass switching allowed Nav  
354 channel labeling at nodes to be verified by co-labeling with K65/35 an IgG1 subclass antibody  
355 directed against CASPR, a protein concentrated at paranodes (41, 42). Similarly, simultaneous  
356 labeling for the highly-related GABA-A receptor  $\beta$ 1 and  $\beta$ 3 subunits (43) with their widely used  
357 respective mAbs N96/55 and N87/25 could not be performed as both are IgG1 subclass.  
358 Switching N96/55 to IgG2a allowed simultaneous detection of these two highly-related but distinct  
359 GABA-A receptor subunits. In Figure 4B localization of GABA-A receptor  $\beta$ 1 and  $\beta$ 3 subunits  
360 appeared completely non-overlapping in separate layers of cerebellum. Figure 4C illustrates  
361 localization of protein Kv2.1 and AnkyrinG in separate subcellular neuronal compartments.  
362 Labeling for the K89/34R R-mAb (IgG2a, red), specific for the Kv2.1 channel, highly expressed in  
363 the plasma membrane of the cell body and proximal dendrites (arrows in panel C1) is shown  
364 together with labeling for N106/65 (green), an IgG1 mAb specific for AnkyrinG, a scaffolding  
365 protein highly expressed in the AIS (arrows in panel C2) and at nodes of Ranvier. Subclass  
366 switching N229A/32 (IgG1, GABA-AR  $\alpha$ 6) to IgG2a, allows comparison with Kv4.2 potassium  
367 channel (K57/1, IgG1) in the cerebellum where both are highly expressed in the granule cell layer  
368 (Figure 4D). While both are prominently found in the glomerular synapses present on the  
369 dendrites of these cells, simultaneous labeling reveals that some cells express both (Figure 4D,  
370 magenta) while others appear to predominantly express Kv4.2 (Figure 4D, blue). Labeling for both



371 proteins is in contrast to that for mAb N147/6 (IgG2b) which recognizes all isoforms of the QKI  
372 transcription factor and labels oligodendrocytes within the granule cell layer and throughout the  
373 Purkinje cell layer (PCL, green). In Figure 4E, localization of pan-QKI (N147/6, IgG2b, blue) is  
374 compared with GFAP (N206A/8, IgG1, green) predominantly thought to be in astrocytes.  
375 Surprisingly many (but not all) cells co-label both proteins. We also labeled cortical neurons with  
376 these two mAbs (pan-QKI in blue, GFAP in green). Multiplex labeling for the neuron-specific Kv2.1  
377 channel, using subclass-switched K89/34R (IgG2a, red) confirms non-neuronal localization of  
378 both proteins. Lastly, we labeled for the postsynaptic scaffold protein PSD-93 using R-mAb  
379 N18/30R (IgG2a, red), which in the cerebellum is prominently localized to Purkinje cell somata  
380 and dendrites (44). As shown in Figure 4F, the R-mAb labeling is consistent with the established  
381 localization of PSD-93. Because of subclass switching the N18/30R R-mAb, this labeling can now  
382 be contrasted with labeling for the excitatory presynaptic terminal marker VGluT1, labeled with  
383 mAb N28/9 (IgG1, blue), which exhibits robust labeling of parallel fiber synapses in the molecular  
384 layer, and glomerular synapses in the granule cell layer. Together these results demonstrate the  
385 utility of employing subclass-switched R-mAbs to obtain labeling combinations not possible with  
386 native mAbs.

387

### 388 **Recovery of Functional R-mAbs from a Non-Viable Hybridoma**

389 While not a common event, mAb-producing B cell hybridomas can lose their mAb production due  
390 to genetic instability (45-47), mycoplasma contamination leading to amino acid depletion and  
391 cytopathic effects (48), or other factors. Non-optimal cryopreservation due to problems during the  
392 freezing process itself or inadequate storage conditions can result in non-recoverable frozen  
393 seeds. As the method described here for cloning of  $V_H$  and  $V_L$  domain sequences from  
394 cryopreserved hybridomas does not require expansion of cells in culture prior to RNA extraction,  
395 we speculated that it may be possible to use this approach to generate functional R-mAbs from  
396 even those hybridoma cell lines that are no longer viable in cell culture.



397 We had in our cryopreserved hybridoma archive a hybridoma cell line that produced the  
398 D3/71 mAb. This hybridoma cell line had been generated in 1994 among a series of projects  
399 targeting the Kv2.1 voltage-gated potassium channel  $\alpha$  subunit, projects that also yielded the  
400 D4/11 mAb (14). The D3/71 mAb has particular value in binding at a site distinct from other anti-  
401 Kv2.1 mAbs. In particular, the binding site for the D3/71 mAb, but not most other available anti-  
402 Kv2.1 mAbs (and pAbs), remains intact in truncated isoforms of Kv2.1 found in patients with  
403 severe neurodevelopmental disorders linked to *de novo* frameshift or nonsense mutations in the  
404 KCNB1 gene (49, 50). Unlike our experience with other cryopreserved hybridomas in our  
405 collection, when we attempted to resuscitate this cryopreserved hybridoma cell line over 20 years  
406 after it was cryopreserved, the D3/71 hybridoma cells were no longer viable in cell culture. We  
407 extracted RNA from a cryopreserved vial of D3/71 hybridoma cells in an attempt to generate a  
408 functional D3/71R R-mAb from these non-viable hybridoma cells. Cloning was performed as  
409 described above including insertion of D3/71 V<sub>H</sub> and V<sub>L</sub> domain cDNA into the mouse IgG2a  
410 expression plasmid (Figs. 5A-B). After bacterial transformation, most of the colonies tested  
411 (20/24) were positive for the insert by PCR (Figure 5C). Restriction analysis of 12 PCR positive  
412 clones confirmed that they each contained the full-length V<sub>L</sub>-joining fragment-V<sub>H</sub> cassette (Figure  
413 5D). We next tested whether these plasmids encoded functional D3/71R R-mAb in double  
414 immunolabeling experiments in Kv2.1-expressing transiently transfected COS-1 cells using a  
415 distinct native anti-Kv2.1 IgG1 mAb K89/34 (51) as a control. We also included a comparison of  
416 D3/71R to the subclass-switched K89/34R R-mAb (31, 52) as an additional control. Two out of 12  
417 clones exhibited specific immunolabeling of Kv2.1-expressing cells as detected with an anti-IgG2a  
418 secondary antibody. An example for one of these is shown in Figure 6A. As shown for one of the  
419 positive clones, the recovered D3/71R R-mAbs exhibited immunolabeling that when detected with  
420 an IgG2a-specific secondary antibody (red) was indistinguishable at both the cellular level in the  
421 specific cells recognized, and at the subcellular level as to the pattern of immunolabeling within  
422 the labeled cells, to that obtained with the K89/34 IgG1 mAb detected with an IgG1-specific

423 secondary antibody (green). Parallel experiments demonstrated successful subclass-switching of  
424 the K89/34 IgG1 mAb when converted into the K89/34R R-mAb (Figure 6B). Moreover, the  
425 D3/71R R-mAb exhibits immunolabeling of endogenous Kv2.1 in neurons in mouse neocortex  
426 that recapitulates the previously established pattern of Kv2.1 immunolabeling in these neurons  
427 [e.g., (31, 53, 54)] and that overlaps precisely with simultaneous immunolabeling obtained with  
428 the native K89/34 mAb (Figure 6C). The D3/71R R-mAb also yields an immunoreactive band on  
429 immunoblots similar to that obtained with K89/34 and K89/34R (Figure 6D). These results suggest  
430 that the mAb cloning approach described here can be used to effectively recover functional R-  
431 mAbs from non-viable hybridomas and could be applied by researchers that have such  
432 hybridomas in their collections.

433

#### 434 **Discussion**

435 In this study, we developed a novel R-mAb generation and validation procedure that we used to  
436 generate a valuable R-mAb resource by converting a library of widely used mouse mAbs into  
437 recombinant reagents. Our approach was adapted from that of Gavin Wright and colleagues (22)  
438 with modifications to facilitate higher throughput cloning and validation steps. The efficiency of  
439 the process was further enhanced by restriction digest of V<sub>L</sub> PCR products to eliminate the MOPC-  
440 21 derived aberrant light chain. R-mAbs were produced in the culture medium from transiently  
441 transfected cells under standard mammalian cell culture conditions in sufficient quantities that  
442 they did not require purification for effective use in IB, ICC, and IHC assays. We were also able  
443 to recover functional R-mAbs from a cryopreserved hybridoma cell line that was no longer viable  
444 in cell culture *via* RNA extraction, cloning and expression. Moreover, in the process we generated  
445 subclass-switched R-mAbs that are more amenable to multiplex labeling in IB, ICC, and IHC  
446 applications. We then employed these mAbs in multiplex IHC experiments in combinations that  
447 were not possible prior to their cloning and expression as subclass-switched R-mAbs. Using the  
448 method described here, most researchers with standard molecular biology expertise can generate

449 functional R-mAb expression plasmids with the advantages associated with recombinant  
450 reagents from their own cryopreserved hybridomas, whether viable or non-viable. Moreover,  
451 producing R-mAbs from cells transfected with any of the large collection of expression plasmids  
452 whose generation is described here is within the reach of anyone with standard mammalian cell  
453 culture capabilities.

454 Building on our long standing and established practice of utilizing mAbs of different IgG  
455 subclasses in simultaneous multiplex immunolabeling experiments (14-17), we previously  
456 undertook a systematic analysis of anti-mouse IgG subclass-specific secondary antibodies. We  
457 demonstrated that the use of mouse mAbs of different IgG subclasses in combination with anti-  
458 mouse IgG subclass-specific secondary antibodies for simultaneous multiplex immunolabeling  
459 allows for robust and specific labeling in several immunolabeling applications, and also provides  
460 enhanced signal-to-noise (background) in immunolabeling of brain samples when compared to  
461 generic anti-mouse IgG (H+L) secondary Abs (18). Simultaneous multiplex labeling of multiple  
462 targets within a single sample allows for better comparison of their relative levels, co-localization,  
463 and overall tissue architecture. Multiplex labeling also conserves valuable samples, as multiple  
464 targets can be interrogated in the same sample instead of across multiple samples, which can be  
465 a particular concern in studies using human tissue samples that may be available in limited  
466 quantity. However, multiplex labeling using the classical approach of employing primary Abs  
467 raised in different species and their subsequent detection with species-specific secondary Abs is  
468 highly limited by the lack of available Abs from numerous species. As one example, interrogating  
469 the Abs registered with the Antibody Registry (2,381,068 as of 9/9/18) shows a preponderance  
470 (84% in total) of Abs raised in only three species: rabbits (44.6%), mice (31.2%) and goats (8.2%),  
471 with all other species together accounting for the remaining 16%. Among the predominant  
472 species, goat Abs are exclusively polyclonal and as such cannot be used with one another in  
473 simultaneous multiplex labeling. Moreover, the bulk of secondary Abs are raised in goats,  
474 constraining facile detection of primary Abs in multiplex labeling experiments employing goat

475 primary Abs. Rabbit Abs (whether poly- or mono-clonal) have limited utility for multiplex labeling,  
476 as unlike most other mammals, rabbits do not make IgGs of distinct subclasses but only a single  
477 generic IgG (55). As such employing multiple goat or rabbit primary Abs for multiplex  
478 immunolabeling involves costly and time-consuming procedures such as direct labeling with  
479 different fluorophores or sequential multiplexing technologies such as Opal™ (56).

480 While the utility of mouse mAbs (and less common rat mAbs) for simultaneous multiple  
481 immunolabeling is enhanced by the availability of subclass-specific secondary antibodies, it  
482 remains that mouse mAbs against any given target may be available in only a single IgG subclass.  
483 In general, mouse mAb collections reflect the representation of these subclasses in the circulating  
484 serum IgGs in immunized BALB/c mice, which is ≈70% IgG1, ≈20% IgG2a and ≈10% IgG2b (57).  
485 As a prominent example, the large mouse mAb catalog of ThermoFisher Scientific (10,992  
486 independent IgG mouse mAbs as of 6/28/18) follows this remarkably closely, comprising 69%  
487 IgG1, 18% IgG2a and 12% IgG2b (Matt Baker, ThermoFisher Scientific, personal  
488 communication). As such, the flexibility of using mouse mAbs in multiplex labeling is restricted by  
489 the preponderance of those of the IgG1 subclass. It is possible to selectively screen for mAbs of  
490 the rarer IgG2a and IgG2b subclasses of mouse IgGs in the process of their development and  
491 screening (24, 58). It is also possible, although labor-intensive, to manipulate hybridomas in  
492 culture and select and/or screen for subclass switched hybridoma-generated mAbs (59).  
493 However, it remains that the optimal utility of mouse mAbs in research and diagnostics is limited  
494 by the preponderance of IgG1 mAbs. Here, we have enhanced the flexibility of a substantial  
495 fraction of an existing library of widely used mouse mAbs by converting them to subclass-switched  
496 R-mAbs without altering target binding specificity. We show using mixtures of mAbs and R-mAb  
497 that we can obtain effective simultaneous multiplex labeling for combinations that were previously  
498 unattainable due to conflicting IgG subclass.

499 Antibody reformatting in our system is easily accomplished by the choice of plasmid  
500 backbone used for the original cloning, or by subcloning the V<sub>L</sub>-joining fragment-V<sub>H</sub> cassette

501 (Figure 1B) between plasmids with distinct C<sub>H</sub> domains. Ultimately, one can envision using this  
502 approach to convert any mouse mAb into the corresponding set of mouse IgG1, IgG2a, and IgG2b  
503 subclass R-mAb expression plasmids. Multiplex labeling could be further expanded by  
504 constructing IgG expression vectors containing C<sub>H</sub> regions of other species that have IgG  
505 subclasses such as rat and human (but not rabbit, in which all IgG Abs are of a generic IgG class),  
506 for which subclass-specific secondary antibodies are also widely available. For example, we  
507 interrogated the ThermoFisher secondary Ab catalog, which contains 52 different IgG subclass-  
508 specific secondary antibodies for mouse IgG subclasses, 47 for rat IgG subclasses, and 43 for  
509 human IgG subclasses. Together, the wide availability of such a broad range of reliable secondary  
510 antibodies with distinct conjugates provides ample flexibility for specific detection of multiple R-  
511 mAbs with distinct C<sub>H</sub> regions engineered for separate detection in multiplex labeling experiments.

512 Previous attempts by others to generate R-mAbs have been complicated by the MOPC-  
513 21 derived aberrant kappa light chain that is present in many widely used myeloma fusion partners  
514 (22, 60-62). For example, Crosnier et al., (22) showed that depending on the hybridoma, 26% to  
515 70% of R-mAb plasmids they generated contained this aberrant sequence. We have incorporated  
516 restriction enzyme digest of this transcript into our process to eliminate the aberrant kappa light  
517 chain (38). For most of our hybridomas, the majority of the V<sub>L</sub> PCR product was cleaved by BciVI,  
518 indicating that the MOPC-21 aberrant light chain comprised the greatest fraction of total light chain  
519 amplicons. By eliminating this transcript, the overall screening and cloning burden for each mAb  
520 was reduced substantially. However, depending on the particular hybridoma, the efficiency of  
521 generating clones that produced functional R-mAbs even after BciVI digestion of the V<sub>L</sub> domain  
522 PCR products was still highly variable. This was evidenced by the overall efficiency of slightly  
523 below 50% for the successful projects tabulated in Table 2, and also by the projects that were  
524 unsuccessful on the first pass in which clones passed the colony PCR and restriction digest  
525 screening steps but failed in the COS-ICC screening assay for functional R-mAbs. Moreover, a  
526 lack of allelic exclusion at heavy and light chain IgG loci has been documented in hybridomas,

527 resulting in expression of multiple IgG heavy and/or light chains at the mRNA and protein levels  
528 (8-10, 63). In these previous studies, while multiple combinations of heavy and light IgG chains  
529 were produced by monoclonal hybridoma cells, only one combination of heavy and light IgG  
530 chains present in the hybridoma produced an R-mAb capable of recognizing the target antigen.  
531 Varying degrees of allelic exclusion in the hybridomas that served as the source of our R-mAbs  
532 could also contribute to the variable efficiency of whether colony PCR and restriction enzyme  
533 assay-positive clones would produce an R-mAb that recapitulated immunolabeling obtained with  
534 the native mAb. Technical issues, such as PCR-induced mutations may have also contributed to  
535 the generation of R-mAb clones that failed in the COS-IF-ICC assay. We did not systematically  
536 analyze these negative clones, so we do not know whether these plasmids contain residual  
537 aberrant light chains from the BciVI digestion step, plasmids containing other heavy and/or light  
538 chains, or mutated forms of *bona fide* R-mAb chains with impaired/lost functionality. That the vast  
539 majority (84%) of the 114 projects for which  $\geq 4$  clones were evaluated yielded at least one positive  
540 R-mAb suggests that the presence of a small and variable number of negative clones does not  
541 impact the overall success of the approach described here, given the simple but effective nature  
542 of microplate screening assays, such as the ICC assay employed here, to rapidly and easily  
543 screen candidate R-mAbs.

544         There is a growing impetus to enhance research reproducibility by both improving the  
545 quality of Abs used in basic research and in diagnostics, and the transparency of their reporting  
546 as related to the exact molecularly-defined Ab that was used (1, 5, 64). Using mAbs in their  
547 recombinant form and defining them unambiguously at the molecular level by publishing their  $V_L$   
548 and  $V_H$  domain sequences is a step towards achieving this goal and elevate reproducibility world-  
549 wide. Among the different forms of research and diagnostic Abs, polyclonal Ab preparations have  
550 unique benefits (65), due to the presence of Abs recognizing distinct epitopes on the target  
551 protein. However, in any of the diverse forms in which they are available (antiserum, IgG fractions,  
552 affinity-purified) polyclonal Abs are inherently limited by their intrinsic lack of precise molecular

553 definition. The inability to rigorously define the clonal composition of specific preparations can  
554 contribute to batch-to-batch variation in the efficacy and specificity of the polyclonal collection for  
555 any specific application, negatively impacting the reproducibility of research performed with such  
556 Abs. Moreover, unlike mAbs, polyclonal Abs are a finite resource whose depletion can lead to  
557 batch-to-batch variability or complete lack of availability, stymieing independent reproduction of  
558 research using the same reagent. Conventional mAbs are advantageous in lacking the molecular  
559 complexity of polyclonal preparations, and in being renewable reagents. However, the conversion  
560 of conventional hybridoma-generated mAbs into R-mAbs offers numerous additional advantages.  
561 This includes ensuring their broad availability by generating a publicly accessible DNA sequence  
562 archive that can be used to synthesize the functional  $V_L$  and  $V_H$  domain sequences. R-mAbs are  
563 also more easily distributed as plasmids or DNA sequence, a feature that should enhance  
564 dissemination of this resource, relative to cryopreserved and living hybridomas that are  
565 comparatively fragile and may not survive long-distance transport. Cloning also enhances  
566 research reproducibility by the unambiguous definition of mAbs at the level of their cDNA  
567 sequence, as well as the enhanced control of molecular composition afforded by expressing a  
568 single light and heavy chain combination from transfected cells and their high-level animal-free  
569 production in cell culture. Cloning of mAbs also allows for increased utility as offered by their  
570 subsequent engineering into alternate forms, such as the subclass-switched R-mAbs generated  
571 here. The method described here represents a straightforward approach to producing functional  
572 R-mAbs from existing murine hybridomas that could be applied to other valuable mAb collections  
573 to ensure their permanent archiving which cannot be assured when they exist solely in the form  
574 of hybridomas cryopreserved in liquid nitrogen. In particular, there are many cases of important  
575 hybridomas, including entire collections, that have been discarded upon the closure of the  
576 laboratory that formerly housed and financially supported the maintenance of the cryopreserved  
577 collection. The enhanced utility, permanence, and cost-effectiveness of R-mAbs as generated by  
578 the approach described here is one route to circumvent the negative impact to research



579 effectiveness and reproducibility that such losses represent. Simple conversion of mAbs to R-  
580 mAbs, as described here, also paves the way for higher throughput approaches, for example  
581 those employing high throughput “next generation” sequencing to simultaneously obtain light and  
582 heavy chain sequences from large pools of hybridomas (66). In theory this should allow for larger  
583 scale “*en masse*” (as opposed to the mAb-by-mAb approach used here) conversion efforts more  
584 suitable to large hybridoma collections. For example, our larger collection of ≈40,000 target-  
585 specific mAbs archived in our cryopreserved hybridoma collection, and other widely used  
586 collections, such as that housed at the Developmental Studies Hybridoma Bank  
587 (<http://dshb.biology.uiowa.edu/>; comprising 3,672 mAbs as of 9/9/18) might represent appropriate  
588 targets for such next generation sequencing approaches. Future efforts to generate R-mAbs from  
589 cryopreserved hybridoma collections will further enhance the rigor, reproducibility and overall  
590 effectiveness of Ab-based research.

591

## 592 **Materials and Methods**

### 593 **Primers**

594 Primer sets for mouse Ig V region amplification and fusion PCR (F-PCR) were used as described  
595 previously (22, 25). The following primers were used for other PCR steps.

596

597 Amplification of the Joining Fragment (22)

598 Primer 21: 5'- GGGCTGATGCTGCACCAACTGTA-3'

599 Primer 26: 5'- ACTGCTTGAGGCTGGACTCGTGAACAATAGCAGC-3'

600

601 Colony PCR:

602 UpNotI: 5'-TTTCAGACCCAGGTACTIONCAT-3'

603 DownAscl: 5'-GGGCAGCAGATCCAGGGGCC-3' (reverse primer for IgG1 vector)

604 Rev IgG2a: 5'- ACCCTTGACCAGGCATCCTAGAGT- 3' (reverse primer for IgG2a vector)



605

606 Mouse  $\gamma$ 2a C<sub>H</sub> domain amplification (restriction sites are underlined):

607 IgG2a-F-Ascl: 5'-ATATCACGGCGCGCCCAACAGCCCCATCGGTCTATCCA-3'

608 IgG2a-R-Xbal: 5'GACTGATCTAGATCATTTACCCGGAGTCCGGGAGAA-3'

609

610 R-mAb Sequencing:

611 Forward strand of V<sub>L</sub> region: UpNotI = 5'-TTTCAGACCCAGGTACTCAT-3'

612 Reverse strand of V<sub>L</sub> region (IgG2a plasmids): Seq\_VL\_Rev\_IgG2a = 5' -  
613 CCAACTGTTCAGGACGCCATT -3'

614 Forward strand of V<sub>H</sub> region: V<sub>H</sub>\_seq\_Forward = 5'- TCCCAGGCCACCATGAA -3'

615 Reverse strand of V<sub>H</sub> region (IgG1 plasmids): DownAscl = 5'-GGGCAGCAGATCCAGGGGCC-3'

616 Reverse strand of V<sub>H</sub> region (IgG2a plasmids): Rev IgG2a = 5'-  
617 ACCCTTGACCAGGCATCCTAGAGT- 3'

618

### 619 **RNA preparation from cryopreserved hybridomas and RT-PCR**

620 The Ambion RNAqueous 96 Extraction kit (Thermo Fisher Cat# AM1920) was used for high  
621 throughput RNA extraction. Frozen vials containing 0.5-1 x 10<sup>7</sup> hybridoma cells per vial were  
622 thawed in a 37°C water bath for 5 minutes, in batches of 20 vials for high through-put purposes.

623 Cells were spun down in a table top centrifuge at 2000 rpm for 5 min, the supernatant was  
624 removed, and cells were washed with 1 mL cold PBS. A 250  $\mu$ L aliquot of this cell suspension  
625 was used for RNA extraction according to the manufacturer's instructions. The Superscript III  
626 Reverse Transcriptase First Strand Synthesis System (Thermo Fisher Cat# 18080051) was used  
627 for high throughput cDNA synthesis in 96 well plates using 4.0  $\mu$ L of RNA per reaction and oligo  
628 (dT) primers.

629

630

### 631 **Immunoglobulin V Region Amplification, BciVI Treatment, and Fusion PCR**

632 Amplification of Ig V region sequences and fusion PCR (F-PCR) to join V<sub>L</sub> and V<sub>H</sub> PCR products  
633 were performed as described (22, 25) with the noted modifications. Briefly, degenerate primer  
634 sets were used to amplify mouse Ig kappa V<sub>L</sub> and V<sub>H</sub> sequences using 1.0 µL of 10-fold diluted,  
635 hybridoma-derived cDNA as a template. PFU Ultra II Fusion HS DNA polymerase (Agilent  
636 Technologies Cat# 600670) and Advantage 2 Polymerase Mix (ClonTech Cat# 639201) were  
637 used for V<sub>L</sub> and V<sub>H</sub> amplification, respectively. PCR conditions for V<sub>L</sub> amplification were: 95°C for  
638 5 minutes; 5 cycles of 95°C for 20 s, 60°C for 20 s, 72°C for 30 s; 19 cycles of 95°C for 20 s,  
639 60.5°C for 20 s with 0.5°C decrement per cycle, 72°C for 30 s; 10 cycles of 95°C for 20 s, 55°C  
640 for 20 s, 72°C for 30 s; 72°C for 15 min. PCR conditions for V<sub>H</sub> amplification were: 95°C for 5  
641 minutes; 5 cycles of 95°C for 45 s, 62°C for 30 s, 72°C for 1 min; 19 cycles of 95°C for 45 s, 64.5°C  
642 for 30 s with 0.5°C decrement per cycle, 72°C for 1 min; 10 cycles of 95°C for 45 s, 55°C for 30  
643 s, 72°C for 1 min; 72°C for 15 min. V<sub>L</sub> PCR products (7.0 µL per reaction) were digested with 5  
644 units of the restriction enzyme BciVI (BfuI) (Thermo Fisher Cat# ER1501) in a 20 µL reaction at  
645 37°C for 2 hrs. The enzyme was inactivated by heating to 80°C for 20 min.

646 In preparation for fusion of the V<sub>L</sub> and V<sub>H</sub> PCR products, a joining fragment was produced  
647 using the mouse Ig expression plasmid P1316 (a gift of Dr. Gavin Wright, Sanger Institute,  
648 Cambridge, UK, now available from Addgene as plasmid #28217). The joining fragment contains  
649 the following sequences (5' to 3'): mouse kappa light chain constant region, a polyadenylation  
650 signal, a CMV promoter, and the leader sequence for the Ig heavy chain. P1316 was used as a  
651 template in a 50 µL PCR containing 0.2 µM of primers 21 and 26, 0.2 mM dNTPs, and 1.0 µL  
652 PFU Ultra II Fusion HS DNA polymerase. PCR conditions were: 95°C for 5 min; 5 cycles of 95°C  
653 for 20 s, 60°C for 20 s, 72°C for 45 s; 19 cycles of 95°C for 20 s, 60.5°C for 20 s with 0.5°C  
654 decrement per cycle, 72°C for 45 s; 10 cycles of 95°C for 20 s, 55°C for 20 s, 72°C for 45 s; 72°C  
655 for 15 min. The 1.7 kb joining fragment was purified (Qiagen/QiaQuick PCR Purification Cat#  
656 28106) in preparation for F-PCR.

657  $V_L$  (BciVI restriction enzyme digested), the joining fragment, and  $V_H$  PCR products were  
658 joined via F-PCR in a 96-well format. We observed that purification of  $V_L$  and  $V_H$  PCR products  
659 was not necessary. Each 50  $\mu$ L reaction consisted of the following: 0.2  $\mu$ M of primers 51 and 52  
660 (22, 25), 0.2 mM dNTPs, 1.5  $\mu$ L  $V_L$  (BciVI digested), 0.5  $\mu$ L  $V_H$ , 0.5  $\mu$ L purified joining fragment  
661 (50 ng), and 1.0  $\mu$ L PFU Ultra II Fusion HS DNA polymerase. PCR conditions were: 95°C for 2  
662 minutes; 11 cycles of 95°C for 45 s, 63°C for 30 s, 72°C for 5 min; 7 cycles of 95°C for 45 s, 62°C  
663 for 30 s with 1°C decrement per cycle, 72°C for 5 min, 95°C for 45 s; 26 cycles of 56°C for 30 s,  
664 72°C for 5 min; 72°C for 15 min.

665

## 666 **Cloning of Immunoglobulin Variable Domain Regions into a Dual Promoter Expression** 667 **Plasmid**

668 F-PCR products were digested with FastDigest NotI and Ascl (Thermo Fisher Cat#  
669 ER0595 and ER1891, respectively) at 37°C for 20 min, followed by inactivation at 80°C for 5 min  
670 and column purification (Qiagen/QiaQuick PCR Purification Cat# 28106). The P1316 plasmid was  
671 also NotI/Ascl digested and gel purified (Qiagen/QiaQuick Gel Extraction Cat# 28706). P1316 is  
672 a derivative of the pTT3 expression vector (26) and consists of (5' to 3'): a CMV promoter, the  
673 mouse V kappa leader sequence, a NotI restriction site, an insert consisting of  $V_L$ /joining  
674 fragment/ $V_H$ , and the mouse IgG1  $C_H$  sequence amplified from mouse genomic DNA, flanked by  
675 Ascl and XbaI restriction sites (22, 25). Ligation was performed overnight at 16°C with T4 DNA  
676 ligase (Thermo Fisher Cat# 15224017) using 20 ng insert and 20 ng vector, a 3:1 molar ratio. Half  
677 of each ligation reaction was used to transform 25  $\mu$ L of Mach I chemically competent *E. coli*.  
678 (Thermo Fisher Cat# C862003). Cells and DNA were incubated on ice for 30 min, heat shocked  
679 at 42°C for 30 s, incubated on ice for 2 min, and allowed to recover for 1.0 hr in 250  $\mu$ L SOC  
680 medium in a 37°C shaking incubator. The cells were spun in a centrifuge at 3000 rpm ( $\approx$ 950 x g)  
681 for 2 min and the supernatant was removed until 150  $\mu$ L remained. Cells were resuspended, and

682 the entire volume was plated on LB plates containing 100 µg/mL ampicillin and incubated  
683 overnight at 37°C.

684

### 685 **Colony PCR, Restriction Analysis and Sequencing of R-mAb Clones**

686 Colony PCR was performed to identify *E. coli* colonies that contained the full-length, 2.4  
687 kb Ig cassette. Colonies were diluted in 96-well plates containing 50 µL water and patch plates  
688 were made for later recovery of positive clones. 2 µL of diluted colony was used in each PCR.  
689 Conditions were 94°C for 5 min; 23 cycles of 94°C for 20 s, 58°C for 30 s, 72°C for 2.5 min; 72°C  
690 for 10 min. For additional confirmation of the presence of the full-length Ig cassette, plasmid DNA  
691 was isolated from PCR positive clones and subjected to restriction enzyme digestion with  
692 NotI/Ascl at 37°C for 20 min followed by agarose gel electrophoresis. The V<sub>L</sub> and V<sub>H</sub> regions of  
693 functional R-mAbs were subjected to sequencing in both orientations to generate a permanent  
694 archive. The primers “UpNotI” and “Seq\_VL\_Rev\_IgG2a” were used for V<sub>L</sub> domain sequencing,  
695 and the “VH seq forward”, and either “DownAscl” or “Rev IgG2a” for sequencing of V<sub>H</sub> regions in  
696 the IgG1 or IgG2a expression plasmids, respectively.

697

### 698 **Generation of a mouse IgG2a expression vector**

699 The mouse γ2a C<sub>H</sub> domain was amplified from the cDNA preparation that was obtained  
700 from the K28/43 (RRID: AB\_2292909) hybridoma (27, 28) that was used for cloning of the K28/43  
701 V<sub>L</sub> and V<sub>H</sub> domains. PCR conditions were: 94°C for 5 min; 29 cycles of 94°C for 30 s, 65°C for 30  
702 s, 72°C for 30 s. The forward primer included an Ascl restriction site and the reverse primer  
703 included an XbaI restriction site to facilitate cloning into the K28/43 IgG1 recombinant R-mAb  
704 plasmid. The K28/43 IgG1 recombinant R-mAb plasmid was derived from the P1316 plasmid (22)  
705 by restriction enzyme-based cloning of K28/43 variable region sequences as described above.  
706 The IgG2a C<sub>H</sub> PCR product and the K28/43 IgG1 recombinant plasmid were both digested with  
707 Ascl and XbaI restriction enzymes (New England BioLabs Cat# R0558 and R0145, respectively)

708 and column purified (Qiagen/QiaQuick PCR Purification Cat# 28106) or agarose gel purified,  
709 respectively (Qiagen/QiaQuick Gel Extraction Cat# 28706). Because XbaI is methylation  
710 sensitive, the K28/43 IgG1 plasmid was sourced from *dam<sup>-</sup>dcm<sup>-</sup> E. coli* (New England Biolabs  
711 Cat# C2925). T4 DNA ligase (New England Biolabs Cat# M0202) was used to insert the IgG2a  
712 C<sub>H</sub> fragment into the digested K28/43R plasmid to generate a K28/43 IgG2a R-mAb plasmid which  
713 was confirmed by DNA sequencing.

714

### 715 **R-mAb Expression in Mammalian Cells**

716 For production of recombinant mAbs in mammalian cell culture, 3 x 10<sup>5</sup> COS-1 cells were  
717 plated on 35 mm tissue culture dishes and cultured overnight in DMEM (high glucose/pyruvate,  
718 Thermo Fisher Cat# 11995065) with 10% Fetal Clone III (HyClone Cat# SH30109.03) and 100  
719 µg/ml penicillin/streptomycin (Thermo Fisher Cat# 15140122). Cells were then transfected with a  
720 1:1 ratio of plasmid (1 µg):Lipofectamine 2000 (1 µL) (Thermo Fisher Cat# 11668019) diluted in  
721 Opti-MEM reduced serum medium (Thermo Fisher Cat# 31985070). Following an overnight  
722 incubation, the transfection solution was replaced with culture medium, and the cells incubated  
723 for an additional six days, at which time the conditioned medium was collected as R-mAb tissue  
724 culture supernatant (TC supe) for analysis.

725

### 726 **COS Cell Immunofluorescence Immunocytochemistry Validation Assay**

727 R-mAb TC supes were screened for immunoreactivity in an immunofluorescence assay  
728 against transiently transfected COS-1 cells cultured in 96-well plates. COS-1 cells were plated in  
729 black, clear bottom 96-well plates (Greiner Cat# 655090) at a density of 4,700 cells/well. After  
730 overnight incubation, each well received 50 ng plasmid DNA encoding the R-mAb target protein  
731 plus Lipofectamine 2000 at a 1:1 ratio as described above. On day 3 post-transfection, cells were  
732 washed 3 times with DPBS (138 mM NaCl, 2.67 mM KCl, 1.47 mM KH<sub>2</sub>PO<sub>4</sub>, 8.1 mM Na<sub>2</sub>HPO<sub>4</sub>, 1  
733 mM CaCl<sub>2</sub> and 1 mM MgCl<sub>2</sub>), pH 7.4 and then fixed using 3.0% formaldehyde (prepared fresh

734 from paraformaldehyde) in DPBS plus 0.1% Triton X-100 on ice for 20 min. Cells were washed  
735 3 times with DPBS/0.1% Triton X-100, blocked with Blotto/0.1% Triton X-100 for 1 hr, and stored  
736 in DPBS/0.02% sodium azide. For primary antibody labeling, R-mAb TC supes were used without  
737 dilution and hybridoma-generated mAb TC supe controls (see Table 4 for details of non-R-mAb  
738 Abs used in this study) were diluted 1:10 in COS-1 cell culture medium. Each R-mAb was tested  
739 alone and in combination with the corresponding hybridoma-generated mAb TC supe. Primary  
740 antibodies were incubated at room temperature for 1 hr and cells were washed 3 x 10 min with  
741 Blotto/0.1% Triton X-100. Secondary labeling was performed at room temperature for 30 min  
742 using subclass-specific, anti-mouse secondary antibodies conjugated to Alexa Fluors (Thermo  
743 Fisher, Cat#/IgG subclass/Alexa Fluor dye conjugates: (A-21121/IgG1/488 and A-  
744 21241/IgG2a/647) and diluted to 1.3 µg/mL in Blotto/0.1% Triton X-100. Hoechst 33342 (Thermo  
745 Fisher Cat# H3570) was used at 0.1 µg/mL in the secondary antibody cocktail to stain nuclear  
746 DNA. Cells were washed 3 x 10 min with DPBS/0.1% Triton X-100. Imaging was performed using  
747 a Zeiss M2 AxioImager microscope. Images were processed using Zeiss Axiovision and ImageJ  
748 software.

749 For higher resolution imaging, COS-1 cells were plated on poly-L-lysine coated #1.5 glass  
750 cover slips and cultured overnight followed by transfection with plasmids encoding the target  
751 protein. Cells were fixed and immunolabeled as described in the previous section. Images were  
752 acquired on a Zeiss AxioImager M2 microscope using a 40x/0.8 NA plan-Apochromat oil-  
753 immersion objective and an AxioCam MRm digital camera. Optical sections were acquired using  
754 an ApoTome 2 structured illumination system (Carl Zeiss MicroImaging). Imaging and post  
755 processing were performed in Axiovision (Carl Zeiss MicroImaging) and Photoshop (Adobe  
756 Systems).

757

758

759

## 760 **Multiplex immunofluorescence labeling of immunoblots**

761 Multiplex immunofluorescence labeling of immunoblots using mouse IgG subclass-  
762 specific secondary antibodies was performed as described previously (18). In brief, samples were  
763 generated from COS-1 cells transiently transfected to express individual target proteins  
764 essentially as described above for the immunofluorescence experiments except that the cells  
765 were cultured in 35 mm tissue cultures dishes. Transfected COS-1 cells were washed once with  
766 ice-cold PBS and lysed with 150  $\mu$ L of ice-cold lysis buffer containing 1% v/v Triton X-100, 150  
767 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl (pH 7.4), 1 mM sodium orthovanadate, 5 mM NaF, 1 mM  
768 PMSF and a protease inhibitor cocktail for 10 min at 4°C (29). The cell lysates were centrifuged  
769 at 12,000 x g at 4 °C for 10 min. The cell lysate supernatants were mixed with 150  $\mu$ L of 2X RSB  
770 and size-fractionated by 7.5% SDS–PAGE. Following SDS-PAGE, proteins were transferred to  
771 nitrocellulose membranes (Bio-Rad Cat# 1620115), which were blocked for 1 h with Blotto (3%  
772 w/v nonfat milk in Tris-buffered saline (TBS: 50 mM Tris, pH 7.5, 150 mM NaCl) plus 0.1% v/v  
773 Tween-20 followed by 2 h or overnight incubation with primary antibodies. Primary antibodies  
774 were mAb TC supes diluted 1:10, non-diluted R-mAb TC supes, and an in-house anti-PSD-95  
775 rabbit polyclonal antibody raised against a GST fusion protein, GSTKAP1.13, containing amino  
776 acids 77–299 of human PSD-95 [clone 2, (30)] and that crossreacts with SAP97 (see Table 4 for  
777 details of non-R-mAb Abs used in this study). After 3 washes with Blotto, the membranes were  
778 incubated with the appropriate subclass-specific Alexa Fluor conjugated secondary antibodies  
779 (18) for 1 h. After 3 washes with TBS containing 0.1% v/v Tween-20, the immunoblots were  
780 visualized directly on a FluorChem Q imager (Cell Biosciences Cat# DE500-FCQ). Alternatively,  
781 crude rat brain membranes (RBM) (29) were subjected to immunoblotting as described above  
782 except that a single RBM sample (3 mg protein) were size fractionated on a curtain gel, and after  
783 transfer to nitrocellulose the membrane was cut into 30 strips, each containing 100  $\mu$ g of RBM  
784 protein. Immunolabeling was detected on autoradiography film after treatment of strip



785 immunoblots with HRP-conjugated anti-mouse IgG-specific secondary antibody and enhanced  
786 chemiluminescence (ECL).

787

### 788 **Multiplex immunofluorescence labeling of brain sections**

789 Multiplex immunofluorescence labeling of brain sections was performed essentially as  
790 described previously (18, 31). All experimental procedures were approved by the UC Davis  
791 Institutional Animal Care and Use Committee and conform to guidelines established by the  
792 National Institutes of Health (NIH). Rats were anesthetized with sodium pentobarbital (Fatal-Plus  
793 solution, 100 mg/kg sodium pentobarbital) and perfused transcardially with 100 mL of phosphate  
794 buffered saline (PBS), containing 10 units/mL heparin, pH 7.4, followed by 400 mL of 4%  
795 formaldehyde (prepared fresh from paraformaldehyde) in 0.1 M sodium phosphate buffer or PB  
796 (pH 7.4). The brains were removed, cryoprotected for 48 hr in 30% sucrose, frozen in a bed of  
797 pulverized dry ice, and then cut into 30  $\mu$ m sections on a freezing-stage sliding microtome.  
798 Sections were collected in 0.1 M PB and processed immediately for immunohistochemistry. Free-  
799 floating brain sections were blocked with 10% goat serum in 0.1 M PB containing 0.3% Triton X-  
800 100 (vehicle) for 1 h at RT and then incubated overnight at 4°C in vehicle containing different  
801 combinations of primary antibodies (see Table 4 for details of non-R-mAb Abs used in this study).  
802 The following day sections were washed 4 X 5 min each with vehicle, and then incubated for 1 h  
803 at RT in mouse IgG subclass-specific or anti-rabbit Alexa-conjugated secondary antibodies as  
804 described previously (18, 32). Sections were then washed 2 X 5 min each with 0.1 M PB, 2 X 5  
805 min each with 0.05 M PB and mounted on gelatin-coated microscope slides and air dried. Sections  
806 were cover slipped after adding ProLong Gold Antifade Mountant (Thermo Fisher Scientific  
807 catalog # P36930). Images were obtained on a Zeiss Axiovert 200 microscope with Apotome.  
808 Imaging and post-imaging processing was performed in Zeiss Axiovision and Adobe Photoshop  
809 software, taking care to maintain any linear differences in signal intensities present in the original  
810 samples.



811 **Table 1. Aberrant V<sub>L</sub> sequences remaining after BciVI digestion**

812

<b>mAb</b>	<b>Number of clones sequenced</b>	<b>Number of clones with aberrant chain</b>	<b>% with aberrant chain</b>
K7/45	5	0	0
K9/40	7	2	28.6
K13/31	10	0	0
K14/16.2	2	0	0
K14/16.2.1	9	2	22.2
K17/70	6	1	16.7
K28/86	3	0	0
K36/15	6	1	16.7
K74/71	6	0	0
K75/41	3	0	0
K87A/10	3	0	0
L6/60	3	0	0
L21/32	4	0	0
L23/27	6	0	0
L61/14	7	1	14.3
N59/20	2	2	100
N70/28	1	0	0
N86/8	8	2	25.0
N86/38	22	0	0
N100/13	6	0	0
N103/31	4	1	25.0
N103/39	5	0	0
N105/13	5	0	0
N106/36	6	0	0
N116/14	3	0	0
N297/59	7	0	0
<b>Total</b>	<b>149</b>	<b>12</b>	<b>8.1</b>

813

814

815 **Table 2. Conversion efficiency of a selected subset of R-mAbs**

816

<b>Successful Projects (130 total)</b>				<b>Unsuccessful Projects (51 total)</b>	
<b>BciVI-resistant (129 total)</b>				<b>BciVI-resistant</b>	
<b>mAb</b>	<b>Colony PCR/Restriction Digest Positives</b>	<b>COS-ICC Positives</b>	<b>% Positive</b>	<b>mAb</b>	<b>Colony PCR/Restriction Digest Positives</b>
D3/71	12	3	25.0	K67/25	2
K7/45	3	1	33.3	K73/20	1
K13/31	3	1	33.3	K78/29	3
K14/16	1	1	100.0	L23/27	3
K19/36	4	3	75.0	L24/18	8
K20/78	6	2	33.3	L48A/9	1
K25/73	8	5	62.5	L57/46	3
K28/86	1	1	100.0	L58A/6	3
K36/15	4	2	25.0	L60/6	2
K37/89	2	1	50.0	L71/5	5
K39/25	5	2	40.0	L76/36	5
K47/42	1	1	100.0	L92/69	6
K51/1	2	1	50.0	L92/70	10
K55/7	5	3	60.0	L92/89	9
K56A/50	4	3	75.0	N18/28	5
K57/1	4	2	50.0	N38/8	6
K64/15	4	3	75.0	N64A/36	1
K66/38	4	3	75.0	N68/6	15
K72/8	3	1	33.3	N71/37	4
K75/41	5	1	20.0	N81/2	5
K91/36	7	3	42.9	N86/8	2
K96/7	2	2	100.0	N86/44	4
L5/1	1	1	100.0	N87/25	3
L8/15	1	1	100.0	N92/14	4

L18A/3	7	2	28.6
L20/8	10	1	10.0
L21/32	11	7	63.6
L42/17	11	4	36.4
L43/40	6	2	33.3
L45/30	9	1	11.1
L51/82	2	1	50.0
L60/4	8	3	37.5
L61/14	4	2	50
N2/16	4	3	75.0
N3/26	8	1	12.5
N6/38	4	1	25.0
N7/18	5	3	60.0
N11/33	13	2	15.4
N15/4	2	1	50.0
N16B/8	3	3	100.0
N18/30	11	3	27.3
N23B/49	2	2	100.0
N28/9	7	4	57.1
N29/29	8	4	50.0
N34/34	3	1	33.3
N50/36	5	1	20.0
N51/6	4	2	50.0
N52A/42	9	4	44.4
N59/36	5	1	20.0
N70/28	3	1	33.3
N77/15	5	1	20.0
N81/37	6	4	66.7
N83/48	4	1	25.0
N84/37	6	4	66.7
N85/18	5	2	40.0
N85/37	6	4	66.7
N86/38	4	2	50.0
N87/25	4	2	50.0
N88/12	6	5	83.3
N93A/49	6	1	16.7
N94/17	6	2	33.3

N95/35	2
N97A/31	2
N105/17	5
N119/44	1
N121A/1	2
N125/10	2
N129/15	3
N134/12	3
N141/28	1
N142/28	5
N144/17	2
N144/32	3
N170A/26	3
N173B/13	4
N183/15	1
N209C/35	3
N212A/34	1
N308/48	6
N319/14	1
N326D/13	2
N330A/80	2
N356/9	2
N363/71	2
N388A/27	3
N399/19	2
N408/79	1
N422/18	4
<b>Total</b>	<b>178</b>

N96/55	6	5	83.3
N104/32	5	2	40.0
N110/29	5	2	40.0
N111/24	3	1	33.3
N112B/14	4	1	25.0
N116/14	7	3	42.9
N117/9	8	5	62.5
N121A/31	6	4	66.7
N124B/38	3	2	66.7
N127/31	9	8	88.9
N129A/6	6	2	33.3
N133/21	4	2	50.0
N135/37	7	1	14.3
N147/6	3	2	66.7
N164/6	2	1	50.0
N168/6	4	1	25.0
N170A/1	5	1	20.0
N171/17	8	2	25.0
N174B/27	3	3	100.0
N176A/35	2	1	50.0
N178A/9	4	2	50.0
N180/41	3	2	66.7
N195A/16	11	3	27.3
N196/16	6	3	50.0
N201/35	2	2	100.0
N205B/22	2	1	50.0
N206A/8	10	1	10.0
N206B/9	7	5	71.4
N212/3	7	4	57.1
N212/7	4	1	25.0
N212/17	8	4	50.0
N222/6	11	4	36.4
N229A/32	8	8	100.0
N230/21	8	3	37.5
N235/22	9	7	77.8
N244/5	7	2	28.6
N268/19	8	1	12.5

N269/73	10	5	50.0
N271/44	2	1	50.0
N277/7	9	2	22.2
N278/19	3	1	33.3
N279B/27	10	10	100.0
N289/16	3	3	100.0
N291C/22	7	5	71.4
N295B/54	5	2	40.0
N295B/66	10	5	50.0
N320/48	9	6	66.7
N321C/49	2	1	50.0
N323B/20	6	4	66.7
N325B/65	4	1	25.0
N326D/29	11	10	90.9
N328B/37	10	2	20.0
N331/19	10	3	30.0
N341/37	6	2	33.3
N346/9	2	2	100.0
N348/82	8	4	50.0
N353/13	6	2	33.3
N355/1	7	4	57.1
N356/23	10	7	70.0
N359/28	7	6	85.7
N388A/10	4	2	50.0
N388A/60	8	1	12.5
N398A/34	11	11	100.0
N413/67	1	1	100.0
N415/24	6	4	66.7
N419/40	13	10	76.9
N419/78	3	1	33.3
1F1	9	4	44.4
<b>Total</b>	<b>741</b>	<b>359</b>	<b>48.4</b>
<b>BciVI-sensitive</b>			
K58/35	19	7	36.8

818 **Table 3. mAbs converted to validated R-mAbs**

819

Clone	Target	mAb IgG subclass	R-mAb IgG subclass	mAb RRID	R-mAb RRID
1F1	TrpC1	IgG1	IgG2A	AB_10999751	AB_2750650
D3/71	Kv2.1 K+ channel	IgG1	IgG2A		AB_2750651
K7/45	Kv1.5	IgG1	IgG2A	AB_10675288	AB_2750674
K9/40	Kvbeta1.1 K+ channel	IgG2b	IgG2A	AB_10672857	AB_2750678
K13/31	Kv1.4 K+ channel	IgG1	IgG2A	AB_10673576	AB_2750652
K14/16	Kv1.2 K+ channel	IgG2b	IgG2A	AB_10674277	AB_2750653
K17/70	Kvbeta2 K+ channel	IgG1	IgG2A	AB_10673520	AB_2750654
K19/36	Kv1.6 K+ channel	IgG3	IgG2A	AB_10671825	AB_2750655
K20/78	Kv1.1 K+ channel	IgG1	IgG2A	AB_10672854	AB_2750656
K25/73	Pan-Kvbeta K+ channel	IgG1	IgG2A	AB_2336914	AB_2750657
K28/43	PSD-95	IgG2a	IgG1	AB_10698024	AB_2750658
K28/43	PSD-95	IgG2a	IgG2A	AB_10698024	AB_2750659
K28/86	Pan-MAGUK	IgG1	IgG2A	AB_10698179	AB_2750660
K36/15	Kv1.1 K+ channel (external)	IgG2b	IgG2A	AB_10673166	AB_2750661
K37/89	Kv2.2 K+ channel	IgG2a	IgG2A	AB_10673393	AB_2750662
K39/25	Kv2.1 K+ channel (external)	IgG2a	IgG2A	AB_10674578	AB_2750663
K40/17	Pan-Kvbeta K+ channel	IgG2a	IgG2A	AB_10672417	AB_2750664
K47/42	Kvbeta1.2 K+ channel	IgG1	IgG2A	AB_10671827	AB_2750665
K51/1	SH3GL1/Endophilin A2	IgG1	IgG2A	AB_10698030	AB_2750666
K55/7	KChIP1 K+ channel	IgG1	IgG2A	AB_10697876	AB_2750667
K55/82	KChIP1 K+ channel	IgG2a	IgG2A	AB_2132595	AB_2750668
K56A/50	CASK	IgG1	IgG2A	AB_10671954	AB_2750669
K57/1	Kv4.2 K+ channel (external)	IgG1	IgG2A	AB_10672254	AB_2750670
K58/35	pan-Nav	IgG1	IgG2A	AB_477552	AB_2750671
K64/15	SAP97	IgG1	IgG2a	AB_10672989	AB_2750672
K66/38	KChIP3 K+ channel	IgG2a	IgG2a	AB_10697878	AB_2750673
K72/8	Co-Rest/RCOR1	IgG1	IgG2A	AB_10673564	AB_2750675
K75/41	Kv4.3 K+ channel	IgG1	IgG2A	AB_10672856	AB_2750676
K89/34	Kv2.1 K+ channel	IgG1	IgG2A	AB_10672253	AB_2750677
K91/36	WAVE1/SCAR	IgG1	IgG2A	AB_10671317	AB_2750679

K96/7	Pancortin	IgG1	IgG2A	AB_10674112	AB_2750680
L5/1	SCG10/Stathmin-2	IgG2b	IgG2A	AB_10671663	AB_2750688
L6/23	Slo1/BKAlpha maxi-K+ channel	IgG1	IgG2A	AB_2493094	AB_2750690
L8/15	SnapiN/SNAPAP	IgG1	IgG2A	AB_10675326	AB_2750694
L18A/3	BKbeta4 K+ channel	IgG2a	IgG2A	AB_10675133	AB_2750681
L20/8	PICK1	IgG2a	IgG2A	AB_10672986	AB_2750682
L21/32	GluA2/GluR2 glutamate receptor	IgG1	IgG2A	AB_10674575	AB_2750683
L28/4	Kv4.2 K+ channel	IgG1	IgG2A	AB_2315873	AB_2750684
L42/17	SynDIG1/Tmem90b	IgG2a	IgG2A	AB_11000166	AB_2750685
L43/40	DLX1	IgG2a	IgG2A	AB_10671701	AB_2750686
L45/30	SynCAM1	IgG1	IgG2A	AB_10671665	AB_2750687
L51/82	MMP9	IgG2a	IgG2A	AB_10672974	AB_2750689
L60/4	Copper ATPase 1 (Menke's disease protein)	IgG2b	IgG2A	AB_10672736	AB_2750691
L61/14	Kv2.1 K+ channel pS603	IgG1	IgG2A	AB_2315769	AB_2750692
L62/29	Copper ATPase 2 (Wilson's disease protein)	IgG1	IgG2A	AB_10672737	AB_2750693
L80/21	Kv2.1 K+ channel	IgG3	IgG2A	AB_2315862	AB_2750695
N2/16	KCNU1/Slo3 maxi-K+ channel	IgG1	IgG2A	AB_10698181	AB_2750743
N3/26	KCNT1/Slo2.2/Slack K+ channel	IgG1	IgG2A	AB_10698032	AB_2750772
N6/38	VACHT	IgG1	IgG2A	AB_10674274	AB_2750807
N7/18	Cavbeta1 Ca2+ channel	IgG2a	IgG2A	AB_10673098	AB_2750809
N8B/1	Cavbeta2 Ca2+ channel	IgG1	IgG2A	AB_10675135	AB_2750822
N10/7	Cavbeta4 Ca2+ channel	IgG1	IgG2A	AB_10671176	AB_2750696
N11/33	KCNT2/Slo2.1/Slick K+ channel	IgG1	IgG2A	AB_10675450	AB_2750700
N15/4	TrpV3	IgG2a	IgG2A	AB_10675455	AB_2750722
N15/39	TrpV3	IgG1	IgG2A	AB_10675456	AB_2750721
N16B/8	Kv3.1b K+ channel	IgG1	IgG2A	AB_10672409	AB_2750730
N18/30	PSD-93/Chapsyn-110	IgG1	IgG2A	AB_10673100	AB_2750737
N19/2	SAP102	IgG1	IgG2A	AB_10671660	AB_2750740
N22/21	Shank1	IgG1	IgG2A	AB_10673108	AB_2750751
N23B/6	Shank2	IgG1	IgG2A	AB_10674119	AB_2750757
N23B/49	Pan-Shank	IgG1	IgG2A	AB_10674115	AB_2750756
N26A/23	Kv7.2/KCNQ2 K+ channel	IgG1	IgG2A	AB_10673164	AB_2750761
N28/9	VGlut1	IgG1	IgG2A	AB_10673111	AB_2750766

N29/29	VGlut2	IgG1	IgG2A	AB_10698039	AB_2750768
N34/34	VGlut3	IgG1	IgG2A	AB_10698040	AB_2750780
N37A/10	Kv7.1/KCNQ1 K+ channel	IgG1	IgG2A	AB_10675286	AB_2750788
N40B/18	BKbeta3a K+ channel	IgG1	IgG2A	AB_10673961	AB_2750792
N49A/21	NGL-1/LRRC4C	IgG1	IgG2A	AB_10671309	AB_2750797
N50/36	NGL-2/LRRC4	IgG1	IgG2A	AB_10697883	AB_2750798
N51/6	NGL-3/LRRC4B	IgG1	IgG2A	AB_10672415	AB_2750799
N52A/42	Mortalin/GRP75	IgG1	IgG2A	AB_10674108	AB_2750800
N52B/27	SALM2/LRFN1	IgG1	IgG2A	AB_10674118	AB_2750801
N53/32	BKbeta2 K+ channel	IgG2a	IgG2A	AB_10674434	AB_2750802
N55/10	Cav3.2 Ca2+ channel	IgG1	IgG2A	AB_2315825	AB_2750803
N56/21	FGF14/FHF4	IgG1	IgG2A	AB_10671703	AB_2750804
N57/2	ADAM22 (extracellular)	IgG1	IgG2A	AB_10671172	AB_2750805
N59/36	GluN2B/NR2B glutamate receptor	IgG2b	IgG2a	AB_10672980	AB_2750806
N69/46	Shank3	IgG2b	IgG2a	AB_10698031	AB_2750808
N70/28	HCN1	IgG1	IgG2A	AB_10672848	AB_2750810
N75/3	mGluR1/5 (Group I) glutamate receptor	IgG2a	IgG2A	AB_10672304	AB_2750811
N76/3	Ataxin-1, 11NQ	IgG1	IgG2A	AB_10673969	AB_2750812
N76/8	Ataxin-1, 11NQ	IgG2b	IgG2A	AB_10671173	AB_2750813
N77/15	TrpC4	IgG2b	IgG2A	AB_10698036	AB_2750814
N81/37	GABA(B)R2	IgG1	IgG2A	AB_10672297	AB_2750815
N83/48	GIT2	IgG1	IgG2A	AB_10672302	AB_2750816
N84/37	Laforin	IgG1	IgG2A	AB_10673395	AB_2750817
N85/18	Malin	IgG1	IgG2A	AB_10673396	AB_2750818
N86/38	GFP	IgG2a	IgG2a	AB_10671955	AB_2750819
N87/25	GABA(A)R, Beta3	IgG1	IgG2a	AB_10673389	AB_2750820
N88/12	MESD	IgG2b	IgG2A	AB_10673280	AB_2750821
N91/27	FGF13/FHF2	IgG1	IgG2A	AB_10675138	AB_2750823
N93A/49	GABA(B)R1	IgG1	IgG2A	AB_10672843	AB_2750824
N94/17	FGF12/FHF1	IgG1	IgG2A	AB_10675137	AB_2750825
N96/55	GABA(A)R, Beta1	IgG1	IgG2A	AB_10673157	AB_2750826
N97A/31	Neuroigin-1	IgG1	IgG2A	AB_10671307	AB_2750827
N98/7	Neuroigin-4*	IgG1	IgG2A	AB_2151948	AB_2750828
N103/39	Aldh1L1 (blotting)	IgG1	IgG2A	AB_10673447	AB_2750697
N104/32	SNAT1	IgG1	IgG2A	AB_10674120	AB_2750698
N106/20	Ankyrin-G (blotting)	IgG1	IgG2A	AB_10674433	AB_2750699



N110/29	Neuroigin-3	IgG1	IgG2A	AB_10673403	AB_2750701
N111/24	Mitofusin-1	IgG1	IgG2A	AB_10675293	AB_2750702
N112B/14	Kir2.1 K+ channel	IgG1	IgG2A	AB_11001668	AB_2750703
N114/10	HCN4	IgG1	IgG2A	AB_10673158	AB_2750704
N116/14	Botch	IgG1	IgG2A	AB_10671697	AB_2750705
N117/9	DNMT3L	IgG1	IgG2A	AB_10673155	AB_2750706
N120A/9	Neuregulin-HBD (Heparin binding domain, Type I/II)	IgG2a	IgG2A	AB_2154679	AB_2750707
N121A/31	Pannexin-2	IgG1	IgG2A	AB_10673509	AB_2750708
N123/19	Histone H3-pThr11	IgG1	IgG2A	AB_10673569	AB_2750709
N124B/38	Kir2.2 K+ channel	IgG1	IgG2A	AB_10697879	AB_2750710
N127/31	Pan-SAPAP	IgG2b	IgG2A	AB_10697886	AB_2750711
N129A/6	Mad3	IgG2b	IgG2A	AB_10674581	AB_2750712
N133/21	RGS14	IgG2a	IgG2A	AB_10698026	AB_2750713
N135/37	JIP-2/IB-2	IgG1	IgG2A	AB_10672307	AB_2750714
N138/6	LRRK2/Dardarin	IgG1	IgG2A	AB_10697869	AB_2750715
N144/14	6xHis	IgG1	IgG2A	AB_10671171	AB_2750716
N144/17	Gamma-protocadherin-A3	IgG1	IgG2A	AB_10697874	AB_2750717
N145/20	Pan-GRK	IgG1	IgG2A	AB_10671656	AB_2750718
N147/6	Pan-QKI	IgG2b	IgG2A	AB_10671658	AB_2750719
N149/25	Olig1	IgG1	IgG2A	AB_10674111	AB_2750720
N150/21	Doc2b	IgG1	IgG2A	AB_2277497	AB_2750723
N151/3	GABA(A)R, Delta	IgG2a	IgG2A	AB_10672295	AB_2750724
N153/5	Mitofusin-2	IgG2a	IgG2A	AB_10672973	AB_2750725
N155/9	Uncx	IgG1	IgG2A	AB_10672528	AB_2750726
N160/21	SynDIG3/Tmem91	IgG2b	IgG2A	AB_10676102	AB_2750727
N164/6	LRP4 (cytoplasmic)	IgG1	IgG2A	AB_10672256	AB_2750728
N168/6	Navbeta4 Na+ channel	IgG1	IgG2A	AB_10673578	AB_2750729
N170A/1	Neurexin-1-Beta	IgG1	IgG2A	AB_10672978	AB_2750731
N170A/26	Neurexin-1-Beta	IgG1	IgG2A	AB_10674585	AB_2750732
N171/17	INPP4b	IgG1	IgG2A	AB_2296057	AB_2750733
N174B/27	Gamma-protocadherin-C3	IgG1	IgG2A	AB_10675141	AB_2750734
N176A/35	S100A5	IgG1	IgG2A	AB_2183799	AB_2750735
N178A/9	Cav3.1 Ca <sup>2+</sup> channel	IgG1	IgG2A	AB_10673097	AB_2750736
N180/41	EAAC1	IgG1	IgG2A	AB_10697871	AB_2750738
N182/17	QKI-6	IgG1	IgG2A	AB_10673511	AB_2750739
N195A/16	QKI-5	IgG1	IgG2A	AB_10676099	AB_2750741

N196/16	PARIS/ZNF746	IgG1	IgG2A	AB_10675299	AB_2750742
N201/35	Iduna/RNF146	IgG1	IgG2A	AB_10675284	AB_2750744
N205B/22	LRRTM4	IgG1	IgG2A	AB_10674105	AB_2750745
N206A/8	GFAP	IgG1	IgG2A	AB_10672298	AB_2750746
N206B/9	GFAP R416WT	IgG1	IgG2A	AB_11000181	AB_2750747
N212/17	TRIP8b (constant)	IgG2a	IgG2A	AB_10675453	AB_2750748
N212/3	TRIP8b (exon 4)	IgG1	IgG2A	AB_2162409	AB_2750749
N212/7	TRIP8b (constant)	IgG2b	IgG2A	AB_10698034	AB_2750750
N222/6	Cln4	IgG1	IgG2A	AB_11001829	AB_2750752
N229A/32	GABA(A)R, Alpha6	IgG1	IgG2A	AB_2336906	AB_2750753
N230/21	MMACHC	IgG1	IgG2A	AB_10673282	AB_2750754
N235/22	Pan-FHF-A	IgG2b	IgG2A	AB_10672416	AB_2750755
N244/5	SynCAM4	IgG1	IgG2A	AB_10673109	AB_2750758
N268/19	TRPML3/Mucolipin-3	IgG2a	IgG2A	AB_11000172	AB_2750759
N269/73	Synaptotagmin-10	IgG1	IgG2A	AB_10672424	AB_2750760
N271/44	ASIC1	IgG1	IgG2A	AB_11000719	AB_2750762
N277/7	Synaptotagmin-12	IgG1	IgG2A	AB_2315939	AB_2750763
N278/19	Synaptotagmin-3	IgG1	IgG2A	AB_11001828	AB_2750764
N279B/27	GluK5/Grik5/KA2 kainate receptor	IgG2a	IgG2A	AB_2315855	AB_2750765
N289/16	SUR1	IgG1	IgG2A	AB_11001671	AB_2750767
N291C/22	TRIP8b (exon 1a/5)	IgG1	IgG2A	AB_2315949	AB_2750769
N295B/54	Arl13b	IgG2b	IgG2A		AB_2750770
N295B/66	Arl13b	IgG2a	IgG2A	AB_11000053	AB_2750771
N320/48	Kirrel3, short isoform 3	IgG2a	IgG2A	AB_11030249	AB_2750773
N321C/49	Kirrel3, short and long	IgG2b	IgG2A	AB_2315856	AB_2750774
N323B/20	SUR2B	IgG2b	IgG2A	AB_2341102	AB_2750775
N325B/65	THAP1	IgG3	IgG2A	AB_2315943	AB_2750776
N326D/29	REEP1/2	IgG1	IgG2A	AB_2315914	AB_2750777
N328B/37	ZNF423	IgG1	IgG2A	AB_2315960	AB_2750778
N331/19	Dopamine D3 receptor	IgG2a	IgG2A	AB_2315831	AB_2750779
N341/37	LRRK1	IgG2a	IgG2A	AB_2315877	AB_2750781
N346/9	Stonin-2	IgG2b	IgG2A	AB_2315923	AB_2750782
N348/82	NSD3	IgG1	IgG2A	AB_2315901	AB_2750783
N353/13	Flrt3	IgG1	IgG2A	AB_2315832	AB_2750784
N355/1	GluA1/GluR1 glutamate receptor	IgG1	IgG2A	AB_2315839	AB_2750785
N356/23	SVOP	IgG1	IgG2A	AB_2315933	AB_2750786

N359/28	Foxi3	IgG1	IgG2A	AB_2315836	AB_2750787
N388A/10	Ankyrin-R	IgG2b	IgG2A	AB_2336901	AB_2750789
N388A/60	Pan-Ankyrin	IgG1	IgG2A	AB_2336913	AB_2750790
N398A/34	GABA(A)R, Alpha4	IgG1	IgG2A	AB_2336905	AB_2750791
N413/67	GABA(A)R, Epsilon	IgG2a	IgG2A	AB_2341105	AB_2750793
N415/24	GABA(A)R, Alpha5	IgG1	IgG2A	AB_2491075	AB_2750794
N419/40	Pan-Nav1 Na <sup>+</sup> channel	IgG2a	IgG2A	AB_2491079	AB_2750795
N419/78	Pan-Nav1 Na <sup>+</sup> channel	IgG1	IgG2A	AB_2491081	AB_2750796

820

821

822 **Table 4. Non-R-mAb antibodies used in this study**

823

<b>Antibody</b>	<b>Immunogen</b>	<b>Manufacturer information</b>	<b>Concentration/dilution used</b>	<b>Figures</b>
<b>KC</b>	Synthetic peptide aa 837-853 of rat Kv2.1	Rabbit pAb, In-house (Trimmer Laboratory), RRID:AB_2315767	Affinity purified, 1:100	4
<b>PSD-95</b>	Fusion protein aa 77-299 of human PSD-95	Rabbit pAb, In-house (Trimmer Laboratory), RRID:AB_2750832	Affinity purified, 1:150	3
<b>K28/43</b>	Fusion protein aa 77-299 of human PSD-95	Mouse IgG2a mAb, NeuroMab RRID:AB_10698024	Tissue culture supernatant, 1:5	3
<b>K28/86</b>	Fusion protein aa 77-299 of human PSD-95	Mouse IgG1 mAb, NeuroMab RRID:AB_10698179	Tissue culture supernatant, 1:5	3
<b>K57/1</b>	Synthetic peptide aa 209-225 of human Kv4.2	Mouse IgG1 mAb, NeuroMab RRID:AB_10672254	Tissue culture supernatant, 1:5	4
<b>K65/35</b>	Fusion protein aa 1308-1381 of rat CASPR	Mouse IgG1 mAb, NeuroMab, RRID:AB_10671175	Tissue culture supernatant, 1:5	4
<b>K89/34</b>	Synthetic peptide aa 837-853 of rat Kv2.1	Mouse IgG1 mAb, NeuroMab catalog #73-014, RRID:AB_10672253	Tissue culture supernatant, 1:10	6
<b>N28/9</b>	Fusion protein aa 492-560 of rat VGluT1	Mouse IgG1 mAb, NeuroMab RRID:AB_10673111	Tissue culture supernatant, 1:5	4
<b>N87/25</b>	Fusion protein aa 370-433 of mouse GABA-A-receptor $\beta$ 3 subunit	Mouse IgG1 mAb, NeuroMab RRID:AB_10673389	Tissue culture supernatant, 1:5	4
<b>N106/65</b>	Full-length recombinant human Ankyrin-G	Mouse IgG2a mAb, NeuroMab RRID:AB_10673449	Tissue culture supernatant, 1:5	4
<b>N147/6</b>	Fusion protein aa 1-341 (full-length) of human QKI-5	Mouse IgG2b mAb, NeuroMab RRID:AB_10671658	Tissue culture supernatant, 1:5	4
<b>N206A/8</b>	Synthetic peptide aa 411-422 of human GFAP	Mouse IgG1 mAb, NeuroMab RRID:AB_10672298	Tissue culture supernatant, 1:5	4

824

825

## 826 References

- 827 1. Taussig MJ, Fonseca C & Trimmer JS (2018) Antibody validation: a view from the  
828 mountains. *N Biotechnol* 45:1-8. DOI: 10.1016/j.nbt.2018.08.002.
- 829 2. Harlow E & Lane D (1988) *Antibodies. A laboratory manual* (Cold Spring Harbor  
830 Laboratory, Cold Spring Harbor, N.Y.) pp 519-538.
- 831 3. Greenfield EA (2014) *Antibodies. A laboratory manual, second edition* (Cold Spring Harbor  
832 Laboratory Press, Cold Spring Harbor, N.Y.).
- 833 4. Busby M, Xue C, Li C, Farjoun Y, Gienger E, Yofe I, Gladden A, Epstein CB, Cornett EM,  
834 Rothbart SB, Nusbaum C & Goren A (2016) Systematic comparison of monoclonal versus  
835 polyclonal antibodies for mapping histone modifications by ChIP-seq. *Epigenetics &*  
836 *chromatin* 9:49. DOI: 10.1186/s13072-016-0100-6.
- 837 5. Bradbury A & Pluckthun A (2015) Reproducibility: Standardize antibodies used in  
838 research. *Nature* 518:27-29. DOI: 10.1038/518027a.
- 839 6. Andreeff M, Bartal A, Feit C & Hirshaut Y (1985) Clonal stability and heterogeneity of  
840 hybridomas: analysis by multiparameter flow cytometry. *Hybridoma* 4:277-287. DOI:  
841 10.1089/hyb.1985.4.277.
- 842 7. Barnes LM, Bentley CM & Dickson AJ (2003) Stability of protein production from  
843 recombinant mammalian cells. *Biotechnol Bioeng* 81:631-639. DOI: 10.1002/bit.10517.
- 844 8. Zack DJ, Wong AL, Stempniak M & Weisbart RH (1995) Two kappa immunoglobulin light  
845 chains are secreted by an anti-DNA hybridoma: implications for isotypic exclusion. *Mol*  
846 *Immunol* 32:1345-1353.
- 847 9. Blatt NB, Bill RM & Glick GD (1998) Characterization of a unique anti-DNA hybridoma.  
848 *Hybridoma* 17:33-39. DOI: 10.1089/hyb.1998.17.33.
- 849 10. Bradbury ARM, Trinklein ND, Thie H, Wilkinson IC, Tandon AK, Anderson S, Bladen CL,  
850 Jones B, Aldred SF, Bestagno M, Burrone O, Maynard J, Ferrara F, Trimmer JS,  
851 Gornemann J, Glanville J, Wolf P, Frenzel A, Wong J, Koh XY, Eng HY, Lane D, Lefranc  
852 MP, Clark M & Dubel S (2018) When monoclonal antibodies are not monospecific:  
853 Hybridomas frequently express additional functional variable regions. *MAbs* 10:539-546.  
854 DOI: 10.1080/19420862.2018.1445456.
- 855 11. Backliwal G, Hildinger M, Chenuet S, Wulhfard S, De Jesus M & Wurm FM (2008) Rational  
856 vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody  
857 titers exceeding 1 g/l by transient transfection under serum-free conditions. *Nucleic Acids*  
858 *Res* 36:e96. DOI: 10.1093/nar/gkn423.
- 859 12. Fischer S, Handrick R & Otte K (2015) The art of CHO cell engineering: A comprehensive  
860 retrospect and future perspectives. *Biotechnol Adv* 33:1878-1896. DOI:  
861 10.1016/j.biotechadv.2015.10.015.
- 862 13. Kunert R & Reinhart D (2016) Advances in recombinant antibody manufacturing. *Appl*  
863 *Microbiol Biotechnol* 100:3451-3461. DOI: 10.1007/s00253-016-7388-9.
- 864 14. Bekele-Arcuri Z, Matos MF, Manganas L, Strassle BW, Monaghan MM, Rhodes KJ &  
865 Trimmer JS (1996) Generation and characterization of subtype-specific monoclonal  
866 antibodies to K<sup>+</sup> channel alpha- and beta-subunit polypeptides. *Neuropharmacology*  
867 35:851-865.
- 868 15. Rhodes KJ, Strassle BW, Monaghan MM, Bekele-Arcuri Z, Matos MF & Trimmer JS  
869 (1997) Association and colocalization of the Kvbeta1 and Kvbeta2 beta-subunits with Kv1  
870 alpha-subunits in mammalian brain K<sup>+</sup> channel complexes. *J Neurosci* 17:8246-8258.
- 871 16. Lim ST, Antonucci DE, Scannevin RH & Trimmer JS (2000) A novel targeting signal for  
872 proximal clustering of the Kv2.1 K<sup>+</sup> channel in hippocampal neurons. *Neuron* 25:385-397.  
873 DOI: S0896-6273(00)80902-2 [pii].
- 874 17. Rasband MN, Park EW, Vanderah TW, Lai J, Porreca F & Trimmer JS (2001) Distinct  
875 potassium channels on pain-sensing neurons. *Proc Natl Acad Sci U S A* 98:13373-13378.

- 876 18. Manning CF, Bundros AM & Trimmer JS (2012) Benefits and pitfalls of secondary  
877 antibodies: why choosing the right secondary is of primary importance. *PLoS One*  
878 7:e38313. DOI: 10.1371/journal.pone.0038313.
- 879 19. Kennedy PJ, Oliveira C, Granja PL & Sarmiento B (2018) Monoclonal antibodies:  
880 technologies for early discovery and engineering. *Crit Rev Biotechnol* 38:394-408. DOI:  
881 10.1080/07388551.2017.1357002.
- 882 20. Wang X, Mathieu M & Brezski RJ (2018) IgG Fc engineering to modulate antibody effector  
883 functions. *Protein Cell* 9:63-73. DOI: 10.1007/s13238-017-0473-8.
- 884 21. Bradbury AR, Sidhu S, Dubel S & McCafferty J (2011) Beyond natural antibodies: the  
885 power of in vitro display technologies. *Nat Biotechnol* 29:245-254. DOI: 10.1038/nbt.1791.
- 886 22. Crosnier C, Staudt N & Wright GJ (2010) A rapid and scalable method for selecting  
887 recombinant mouse monoclonal antibodies. *BMC Biol* 8:76. DOI: 10.1186/1741-7007-8-  
888 76.
- 889 23. Rhodes KJ & Trimmer JS (2006) Antibodies as valuable neuroscience research tools  
890 versus reagents of mass distraction. *J Neurosci* 26:8017-8020. DOI: 10.1523/JNEUROSCI.2728-06.2006.  
891 10.1523/JNEUROSCI.2728-06.2006.
- 892 24. Gong B, Murray KD & Trimmer JS (2016) Developing high-quality mouse monoclonal  
893 antibodies for neuroscience research - approaches, perspectives and opportunities. *N*  
894 *Biotechnol* 33:551-564. DOI: 10.1016/j.nbt.2015.11.007.
- 895 25. Muller-Siennerth N, Crosnier C, Wright GJ & Staudt N (2014) Cloning of recombinant  
896 monoclonal antibodies from hybridomas in a single mammalian expression plasmid.  
897 *Methods Mol Biol* 1131:229-240. DOI: 10.1007/978-1-62703-992-5\_14.
- 898 26. Durocher Y, Perret S & Kamen A (2002) High-level and high-throughput recombinant  
899 protein production by transient transfection of suspension-growing human 293-EBNA1  
900 cells. *Nucleic Acids Res* 30:E9.
- 901 27. Rasband MN, Park EW, Zhen D, Arbuckle MI, Poliak S, Peles E, Grant SG & Trimmer JS  
902 (2002) Clustering of neuronal potassium channels is independent of their interaction with  
903 PSD-95. *J Cell Biol* 159:663-672.
- 904 28. Shibata R, Misonou H, Campomanes CR, Anderson AE, Schrader LA, Doliveira LC,  
905 Carroll KI, Sweatt JD, Rhodes KJ & Trimmer JS (2003) A fundamental role for KChIPs in  
906 determining the molecular properties and trafficking of Kv4.2 potassium channels. *J Biol*  
907 *Chem* 278:36445-36454.
- 908 29. Shi G, Kleinklaus AK, Marrion NV & Trimmer JS (1994) Properties of Kv2.1 K<sup>+</sup> channels  
909 expressed in transfected mammalian cells. *J Biol Chem* 269:23204-23211.
- 910 30. Kim E, Niethammer M, Rothschild A, Jan YN & Sheng M (1995) Clustering of Shaker-type  
911 K<sup>+</sup> channels by interaction with a family of membrane-associated guanylate kinases.  
912 *Nature* 378:85-88. DOI: 10.1038/378085a0.
- 913 31. Bishop HI, Guan D, Bocksteins E, Parajuli LK, Murray KD, Cobb MM, Misonou H, Zito K,  
914 Foehring RC & Trimmer JS (2015) Distinct cell- and layer-specific expression patterns and  
915 independent regulation of Kv2 channel subtypes in cortical pyramidal neurons. *J Neurosci*  
916 35:14922-14942. DOI: 10.1523/JNEUROSCI.1897-15.2015.
- 917 32. Strassle BW, Menegola M, Rhodes KJ & Trimmer JS (2005) Light and electron  
918 microscopic analysis of KChIP and Kv4 localization in rat cerebellar granule cells. *J Comp*  
919 *Neurol* 484:144-155. DOI: 10.1002/cne.20443.
- 920 33. Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR & Pluckthun  
921 A (1997) Reliable cloning of functional antibody variable domains from hybridomas and  
922 spleen cell repertoires employing a reengineered phage display system. *J Immunol*  
923 *Methods* 201:35-55.
- 924 34. Houghton G, Lanier LL & Babcock GF (1978) The murine kappa light chain shift. *Nature*  
925 275:154-157.



- 926 35. Woloschak GE & Krco CJ (1987) Regulation of kappa/lambda immunoglobulin light chain  
927 expression in normal murine lymphocytes. *Mol Immunol* 24:751-757.
- 928 36. Carroll WL, Mendel E & Levy S (1988) Hybridoma fusion cell lines contain an aberrant  
929 kappa transcript. *Mol Immunol* 25:991-995.
- 930 37. Shulman M, Wilde CD & Kohler G (1978) A better cell line for making hybridomas secreting  
931 specific antibodies. *Nature* 276:269-270.
- 932 38. Juste M, Muzard J & Billiald P (2006) Cloning of the antibody kappa light chain V-gene  
933 from murine hybridomas by bypassing the aberrant MOPC21-derived transcript. *Anal*  
934 *Biochem* 349:159-161. DOI: 10.1016/j.ab.2005.10.046.
- 935 39. Kistner U, Wenzel BM, Veh RW, Cases-Langhoff C, Garner AM, Appeltauer U, Voss B,  
936 Gundelfinger ED & Garner CC (1993) SAP90, a rat presynaptic protein related to the  
937 product of the *Drosophila* tumor suppressor gene *dlg-A*. *J Biol Chem* 268:4580-4583.
- 938 40. Rasband MN, Peles E, Trimmer JS, Levinson SR, Lux SE & Shrager P (1999)  
939 Dependence of nodal sodium channel clustering on paranodal axoglial contact in the  
940 developing CNS. *J Neurosci* 19:7516-7528.
- 941 41. Menegoz M, Gaspar P, Le Bert M, Galvez T, Burgaya F, Palfrey C, Ezan P, Arnos F &  
942 Girault JA (1997) Paranodin, a glycoprotein of neuronal paranodal membranes. *Neuron*  
943 19:319-331.
- 944 42. Peles E, Nativ M, Lustig M, Grumet M, Schilling J, Martinez R, Plowman GD &  
945 Schlessinger J (1997) Identification of a novel contactin-associated transmembrane  
946 receptor with multiple domains implicated in protein-protein interactions. *Embo j* 16:978-  
947 988. DOI: 10.1093/emboj/16.5.978.
- 948 43. Zhang JH, Sato M & Tohyama M (1991) Region-specific expression of the mRNAs  
949 encoding beta subunits (beta 1, beta 2, and beta 3) of GABAA receptor in the rat brain. *J*  
950 *Comp Neurol* 303:637-657. DOI: 10.1002/cne.903030409.
- 951 44. Brenman JE, Topinka JR, Cooper EC, McGee AW, Rosen J, Milroy T, Ralston HJ & Bredt  
952 DS (1998) Localization of postsynaptic density-93 to dendritic microtubules and interaction  
953 with microtubule-associated protein 1A. *J Neurosci* 18:8805-8813.
- 954 45. Morrison SL & Scharff MD (1981) Mutational events in mouse myeloma cells. *Crit Rev*  
955 *Immunol* 3:1-22.
- 956 46. Frame KK & Hu WS (1990) The loss of antibody productivity in continuous culture of  
957 hybridoma cells. *Biotechnol Bioeng* 35:469-476. DOI: 10.1002/bit.260350504.
- 958 47. Castillo FJ, Mullen LJ, Grant BC, DeLeon J, Thrift JC, Chang LW, Irving JM & Burke DJ  
959 (1994) Hybridoma stability. *Dev Biol Stand* 83:55-64.
- 960 48. Drexler HG & Uphoff CC (2002) Mycoplasma contamination of cell cultures: Incidence,  
961 sources, effects, detection, elimination, prevention. *Cytotechnology* 39:75-90. DOI:  
962 10.1023/A:1022913015916.
- 963 49. de Kovel CG, Brilstra EH, van Kempen MJ, Van't Slot R, Nijman IJ, Afawi Z, De Jonghe  
964 P, Djemie T, Guerrini R, Hardies K, Helbig I, Hendrickx R, Kanaan M, Kramer U, Lehesjoki  
965 AE, Lemke JR, Marini C, Mei D, Moller RS, Pendziwiat M, Stamberger H, Suls A,  
966 Weckhuysen S, Euro ERESA & Koeleman BP (2016) Targeted sequencing of 351  
967 candidate genes for epileptic encephalopathy in a large cohort of patients. *Mol Genet*  
968 *Genomic Med* 4:568-580. DOI: 10.1002/mgg3.235.
- 969 50. Marini C, Romoli M, Parrini E, Costa C, Mei D, Mari F, Parmeggiani L, Procopio E, Metitieri  
970 T, Cellini E, Virdo S, De Vita D, Gentile M, Prontera P, Calabresi P & Guerrini R (2017)  
971 Clinical features and outcome of 6 new patients carrying de novo KCNB1 gene mutations.  
972 *Neurol Genet* 3:e206. DOI: 10.1212/NXG.0000000000000206.
- 973 51. Misonou H, Mohapatra DP, Park EW, Leung V, Zhen D, Misonou K, Anderson AE &  
974 Trimmer JS (2004) Regulation of ion channel localization and phosphorylation by neuronal  
975 activity. *Nat Neurosci* 7:711-718. DOI: 10.1038/nn1260nn1260 [pii].



- 976 52. Mandikian D, Bocksteins E, Parajuli LK, Bishop HI, Cerda O, Shigemoto R & Trimmer JS  
977 (2014) Cell type-specific spatial and functional coupling between mammalian brain Kv2.1  
978 K(+) channels and ryanodine receptors. *J Comp Neurol* 522:3555-3574. DOI:  
979 10.1002/cne.23641.
- 980 53. Trimmer JS (1991) Immunological identification and characterization of a delayed rectifier  
981 K+ channel polypeptide in rat brain. *Proc Natl Acad Sci U S A* 88:10764-10768.
- 982 54. Rhodes KJ, Keilbaugh SA, Barrezueta NX, Lopez KL & Trimmer JS (1995) Association  
983 and colocalization of K+ channel alpha- and beta-subunit polypeptides in rat brain. *J*  
984 *Neurosci* 15:5360-5371.
- 985 55. Knight KL, Burnett RC & McNicholas JM (1985) Organization and polymorphism of rabbit  
986 immunoglobulin heavy chain genes. *J Immunol* 134:1245-1250.
- 987 56. Stack EC, Wang C, Roman KA & Hoyt CC (2014) Multiplexed immunohistochemistry,  
988 imaging, and quantitation: a review, with an assessment of Tyramide signal amplification,  
989 multispectral imaging and multiplex analysis. *Methods* 70:46-58. DOI:  
990 10.1016/j.ymeth.2014.08.016.
- 991 57. Natsuume-Sakai S, Motonishi K & Migita S (1977) Quantitative estimations of five classes  
992 of immunoglobulin in inbred mouse strains. *Immunology* 32:861-866.
- 993 58. Liu H, White J, Crawford F, Jin N, Ju X, Liu K, Jiang C, Marrack P, Zhang G & Kappler JW  
994 (2015) A rapid method to characterize mouse IgG antibodies and isolate native antigen  
995 binding IgG B cell hybridomas. *PLoS One* 10:e0136613. DOI:  
996 10.1371/journal.pone.0136613.
- 997 59. Faguet GB & Agee JF (1993) A simple technique for the rapid enrichment of class and  
998 subclass hybridoma switch variants. A 1000-fold enrichment in half the time, for half the  
999 cost. *J Immunol Methods* 165:217-224.
- 1000 60. Cochet O, Martin E, Fridman WH & Teillaud JL (1999) Selective PCR amplification of  
1001 functional immunoglobulin light chain from hybridoma containing the aberrant MOPC 21-  
1002 derived V kappa by PNA-mediated PCR clamping. *Biotechniques* 26:818-820, 822.
- 1003 61. Duan L & Pomerantz RJ (1994) Elimination of endogenous aberrant kappa chain  
1004 transcripts from sp2/0-derived hybridoma cells by specific ribozyme cleavage: utility in  
1005 genetic therapy of HIV-1 infections. *Nucleic Acids Res* 22:5433-5438.
- 1006 62. Yuan X, Gubbins MJ & Berry JD (2004) A simple and rapid protocol for the sequence  
1007 determination of functional kappa light chain cDNAs from aberrant-chain-positive murine  
1008 hybridomas. *J Immunol Methods* 294:199-207. DOI: 10.1016/j.jim.2004.09.001.
- 1009 63. Ruberti F, Cattaneo A & Bradbury A (1994) The use of the RACE method to clone  
1010 hybridoma cDNA when V region primers fail. *J Immunol Methods* 173:33-39.
- 1011 64. Uhlen M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E, Rimm DL,  
1012 Rodriguez H, Hiltke T, Snyder M & Yamamoto T (2016) A proposal for validation of  
1013 antibodies. *Nat Methods* 13:823-827. DOI: 10.1038/nmeth.3995.
- 1014 65. Ascoli CA & Aggeler B (2018) Overlooked benefits of using polyclonal antibodies.  
1015 *Biotechniques*. DOI: 10.2144/btn-2018-0065.
- 1016 66. Chen Y, Kim SH, Shang Y, Guillory J, Stinson J, Zhang Q, Hotzel I & Hoi KH (2018)  
1017 Barcoded sequencing workflow for high throughput digitization of hybridoma antibody  
1018 variable domain sequences. *J Immunol Methods* 455:88-94. DOI:  
1019 10.1016/j.jim.2018.01.004.
- 1020

1021 **Figure legends**

1022 **Figure 1. Schematic representation of the R-mAb pipeline.** A. Schematic of cloning,  
1023 expression and validation pipeline. Orange steps involve  $V_H$  and  $V_L$  regions of individual  
1024 hybridomas, blue steps involve steps involving backbone components, and green step involves  
1025 expression of target for R-mAb validation. B. Schematic shows the separate elements of the R-  
1026 mAb expression plasmid involved in coexpression of light (green) and heavy (blue) chains as  
1027 driven by two CMV promoters (orange). Hybridoma-derived  $V_L$  and  $V_H$  domain PCR products are  
1028 fused to a joining fragment comprising a  $\kappa$  light chain constant domain ( $C_L$ ) and the  $\kappa$  light chain  
1029 polyA tail sequences ( $\kappa$  pA), a CMV promoter for heavy chain expression, and an ER signal/leader  
1030 sequence (L) for translocation of the heavy chain across the ER membrane. PCR-mediated fusion  
1031 of these three elements is followed by their insertion into the p1316 plasmid that contains an  
1032 upstream CMV promoter for light chain expression, and an ER signal/leader sequence (L) for  
1033 translocation of the light chain across the ER membrane. Downstream of the insert is a heavy  
1034 chain constant domain ( $C_H$ ) that is either  $\gamma 1$  or  $\gamma 2a$  depending on the plasmid, followed by the  
1035 SV40 polyA tail (SV40 pA).

1036

1037 **Figure 2. Cloning of  $V_L$  and  $V_H$  domain sequences from hybridomas into the R-mAb**  
1038 **expression plasmid.** A. Agarose gel analysis of  $V_L$  and  $V_H$  domain PCR products amplified from  
1039 cDNA synthesized from RNA extracted from the N59/36 (anti-NR2B/GRIN2B) and K39/25 (anti-  
1040 Kv2.1/KCNB1) hybridomas. The expected size of mouse IgG  $V_L$  and  $V_H$  domains is  $\approx 360$  bp. B.  
1041 Agarose gel analysis of  $V_H$  and digested  $V_L$  fragments joined by fusion PCR (F-PCR) to the  
1042 P1316-derived joining fragment to create a dual IgG chain cassette. C. Agarose gel analysis of  
1043 colony PCR samples of transformants from the N59/36 R-mAb project. D. Agarose gel analysis  
1044 of products of restriction enzyme digestion of N59/36 plasmid DNA with NotI and Ascl. The  
1045 plasmid backbone is 7 kbp, and the intact insert comprising the  $V_L$  and  $V_H$  domains and the  
1046 intervening joining fragment is 2.4 kbp. E. Agarose gel analysis of PCR products of  $V_L$  domain

1047 cDNA synthesized from RNA extracted from mouse splenocytes, the fusion partner Sp2/0-Ag14,  
1048 and various hybridomas after digestion with the BciVI restriction enzyme to cleave the Sp2/0-  
1049 Ag14-derived aberrant light chain product. The intact V<sub>L</sub> domains are ≈360 bp, and the digested  
1050 aberrant light chains ≈180 bp.

1051

1052 **Figure 3. Validation of subclass-switched anti-PSD-95 K28/43R R-mAb.** A. Validation of the  
1053 K28/43R R-mAb in heterologous cells. COS-1 cells transiently transfected to express human  
1054 PSD-95 in a subset of cells were immunolabeled with K28/43 mAb (IgG2a) alone (top row),  
1055 K28/43R R-mAb (IgG1) alone (middle row), or K28/43 mAb plus K28/43R R-mAb (bottom row).  
1056 Immunolabeling in all samples was detected with a cocktail of anti-mouse IgG2a (red, for the  
1057 K28/43 mAb) and anti-mouse IgG1 (green, for the K28/43R R-mAb) subclass-specific Alexa Fluor  
1058 conjugated secondary antibodies. Labeling in blue is for the DNA-specific dye Hoechst 33258 and  
1059 shows nuclei of both transfected and untransfected cells. Scale bar in the lower right merged  
1060 panel = 30 μm and holds for all panels in A. B. Validation of the K28/43R R-mAb in brain sections.  
1061 A brain section from an adult rat was immunolabeled with K28/43 mAb plus K28/43R R-mAb and  
1062 immunolabeling detected with a cocktail of anti-mouse IgG2a (red, for K28/43 mAb) and anti-  
1063 mouse IgG1 (green, for K28/43R R-mAb) subclass-specific Alexa Fluor conjugated secondary  
1064 antibodies. Cell nuclei are labeled with the DNA-specific dye Hoechst 33258 (blue). The region of  
1065 interest shown is from cerebellar cortex. Scale bar in the left panel = 100 μm, and in the right  
1066 merged panel = 30 μm. C-E. Immunoblots against COS cell lysates over-expressing various  
1067 members of the MAGUK superfamily of scaffolding proteins. To confirm expression of MAGUK  
1068 proteins, immunoblots were probed with rabbit anti-PSD-95 (red). Primary antibodies were  
1069 detected with the appropriate combinations of fluorescently labeled species-specific anti-rabbit  
1070 and subclass-specific anti-mouse IgG secondary Abs. Control indicates COS cells transfected  
1071 with an empty vector. C. K28/43R R-mAb (IgG2a, green). D. K28/43R R-mAb (IgG1, blue). E. the

1072 K28/43 mAb (IgG2a, green). The blot in E was also probed with the K28/86 mAb (anti-pan-  
1073 MAGUK, IgG1, blue).

1074

1075 **Figure 4. Multiplex immunolabeling with subclass-switched recombinant antibodies in**

1076 **adult rat brain.** A. Sections from neocortex labeled with anti-pan-Nav R-mAb K58/35R (IgG2a,

1077 red) at nodes of Ranvier and AIS, anti-CASPR mAb K65/35 (IgG1, green) at paranodes, and anti-

1078 Kv2.1 rabbit polyclonal (KC) antibody (blue) on somata and proximal dendrites. Scale bar = 150

1079  $\mu\text{m}$ . Insets (dashed box) show details of labeling for pan-Nav (red) and CASPR (green) at a single

1080 node of Ranvier as indicated by box in main panel. B. Sections through cerebellum show labeling

1081 with anti-GABA-AR  $\beta 1$  R-mAb N96/55R (IgG2a, magenta) in the molecular layer (ML), and anti-

1082 GABA-AR  $\beta 3$  mAb N87/25 (IgG1, green) in the granule cell layer (GL). PCL = Purkinje cell layer.

1083 Scale bar = 150  $\mu\text{m}$ . C. Hippocampus sections labeled with anti-Kv2.1 R-mAb 89/34R (IgG2a,

1084 red) on somata and proximal dendrites, anti-AnkyrinG mAb N106/65 (IgG2b, green) on AIS, and

1085 nuclear stain Hoechst 33258 (blue). Scale bar = 150  $\mu\text{m}$ . Panels C1-C3 show magnified details

1086 of labeling for pan-Kv2.1 (red) on somata and proximal dendrites, and anti-AnkyrinG (green) on

1087 AIS. Scale bar = 50  $\mu\text{m}$  (C1-C3). D. Sections through cerebellum labelled with anti-GABA-AR  $\alpha 6$

1088 R-mAb K229A/32R (IgG2a, red) in the granule cell layer (GL), anti-pan-QKI mAb N147/6 (IgG2b,

1089 green) labeling glial cells in/near the Purkinje cell layer (PCL), and anti-Kv4.2 mAb K57/1 (IgG1,

1090 blue) labeling the granule cell layer (GL). Scale bar = 30  $\mu\text{m}$ . E. Sections from neocortex labelled

1091 with anti-Kv2.1 R-mAb 89/34R (IgG2a, red) on somata and proximal dendrites of neurons, and

1092 anti-GFAP mAb N206A/8 (IgG1, green) and anti-pan-QKI mAb N147/6 (IgG2b, blue) labeling glial

1093 cell processes and cell bodies respectively. Scale bar = 15  $\mu\text{m}$ . F. Sections through cerebellum

1094 show labeling with anti-PSD-93 R-mAb N18/30R (IgG2a, red) in the cell bodies and dendrites of

1095 Purkinje cells, the nuclear stain Hoechst 33258 (green) and anti-VGluT1 mAb N28/9 (IgG1, blue)


1096 in the molecular layer (ML). PCL = Purkinje cell layer. Scale bar = 10  $\mu\text{m}$ .

1097 **Figure 5. Cloning of anti-Kv2.1 D3/71 V<sub>L</sub> and V<sub>H</sub> domain cDNAs from a nonviable**  
1098 **hybridoma.** A. Agarose gel analysis of PCR amplified V<sub>L</sub> and V<sub>H</sub> domains from cDNA synthesized  
1099 from RNA extracted from the non-viable D3/71 hybridoma. The panel to the right shows the V<sub>L</sub>  
1100 after digestion with the BciVI restriction enzyme to cleave the Sp2/0-Ag14-derived aberrant light  
1101 chain product. The expected size of mouse IgG V<sub>L</sub> and V<sub>H</sub> domains is ≈360 bp, and of the cleaved  
1102 aberrant V<sub>L</sub> domain is ≈180 bp. B. Agarose gel analysis of D3/71 V<sub>H</sub> and digested V<sub>L</sub> fragments  
1103 joined by fusion PCR (F-PCR) to the P1316 joining fragment to create a dual IgG chain cassette.  
1104 C. Agarose gel analysis of colony PCR samples of transformants from the of D3/71 R-mAb  
1105 project. D. Agarose gel analysis of products of restriction enzyme digestion of D3/71 plasmid DNA  
1106 with NotI and Ascl. The plasmid backbone is 7 kbp, and the intact insert comprising the V<sub>L</sub> and  
1107 V<sub>H</sub> domains and the intervening joining fragment is 2.4 kbp.

1108  
1109 **Figure 6. Recovery of a functional anti-Kv2.1 D3/71R R-mAb from nonviable hybridomas.**


1110 A. Validation of the D3/71R R-mAb in heterologous cells. COS-1 cells transiently transfected to  
1111 express rat Kv2.1 in a subset of cells were immunolabeled with K89/34 mAb (IgG1) alone (top  
1112 row), D3/71R R-mAb (IgG2a) alone (middle row), or K89/34 mAb plus D3/71R R-mAb (bottom  
1113 row). Immunolabeling in all samples was detected with a cocktail of anti-mouse IgG1 (green, for  
1114 the K89/34 mAb) and anti-mouse IgG2a (red, for the D3/71R R-mAb) subclass-specific Alexa  
1115 Fluor conjugated secondary antibodies. B. Validation of the subclass-switched K89/34R R-mAb  
1116 in heterologous cells. COS-1 cells transiently transfected to express rat Kv2.1 in a subset of cells  
1117 were immunolabeled with K89/34 mAb (IgG1) alone (top row), K89/34R R-mAb (IgG2a) alone  
1118 (middle row), or K89/34 mAb plus K89/34R R-mAb (bottom row). Immunolabeling in all samples  
1119 was detected with a cocktail of anti-mouse IgG1 (green, for the K89/34 mAb) and anti-mouse  
1120 IgG2a (red, for the K89/34R R-mAb) subclass-specific Alexa Fluor conjugated secondary  
1121 antibodies. Labeling in blue in panels A and B is for the DNA-specific dye Hoechst 33258 and  
1122 shows nuclei of both transfected and untransfected cells. Scale bar in the lower right merged

1123 panel = 30  $\mu$ m and holds for all panels in A and B. C. Validation of the D3/71R R-mAb in brain  
1124 sections. A brain section from an adult rat was immunolabeled with K89/34 mAb plus D3/71 R-  
1125 mAb and the immunolabeling detected with a cocktail of anti-mouse IgG1 (green, for the K89/34  
1126 mAb) and anti-mouse IgG2a (red, for the D3/71R R-mAb) subclass-specific Alexa Fluor  
1127 conjugated secondary antibodies. Cell nuclei are labeled with the DNA-specific dye Hoechst  
1128 33258 (blue). Region of interest shown is from neocortex. Scale bar = 30  $\mu$ m. D. Strip  
1129 immunoblots on a crude rat brain membrane fraction immunolabeled with the K89/34 mAb, the  
1130 K89/34R R-mAb, and the D3/71 R-mAb as indicated. Immunolabeling was detected on  
1131 autoradiography film after treatment of strip immunoblots with HRP-conjugated anti-mouse IgG-  
1132 specific secondary antibody and ECL.  
1133



**Figure 1**










Figure 3







Figure 4



**Figure 5**






Figure 6